Fei (FEIC) 10-Q 2016 Q2 Quarterly report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 _____________________________________________

FORM 10-Q

 _____________________________________________

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended July 3, 2016

OR

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. 000-22780

 _____________________________________________

FEI COMPANY

(Exact name of registrant as specified in its charter)

 _____________________________________________

Oregon	93-0621989
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
5350 NE Dawson Creek Drive, Hillsboro, Oregon	97124-5793
(Address of principal executive offices)	(Zip Code)
503-726-7500
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	x		Accelerated filer	o
Non-accelerated filer	o	(Do not check if a smaller reporting company)	Smaller reporting company	o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  o No  x

The number of shares of common stock outstanding as of August 1, 2016 was 41,015,658.

FEI COMPANY

FORM 10-Q QUARTERLY REPORT

TABLE OF CONTENTS

		Page
PART I - FINANCIAL INFORMATION
Item 1.	Financial Statements (Unaudited)
	Consolidated Balance Sheets as of July 3, 2016 and December 31, 2015	2
	Consolidated Statements of Operations for the thirteen and twenty-six weeks ended July 3, 2016 and June 28, 2015	3
	Consolidated Statements of Comprehensive Income for the thirteen and twenty-six weeks ended July 3, 2016 and June 28, 2015	4
	Consolidated Statements of Cash Flows for the twenty-six weeks ended July 3, 2016 and June 28, 2015	5
	Condensed Notes to the Consolidated Financial Statements	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	30
Item 4.	Controls and Procedures	30
PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	31
Item 1A.	Risk Factors	31
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	43
Item 6.	Exhibits	44
Signatures		45

1

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

FEI Company and Subsidiaries

Consolidated Balance Sheets

(In thousands)

(Unaudited)

	July 3, 2016			December 31, 2015
Assets
Current Assets:
Cash and cash equivalents	$	317,345		$	300,911
Restricted cash	8,330			19,119
Receivables, net of allowances for doubtful accounts of $2,118 and $2,789	233,627			213,128
Inventories	200,304			170,513
Deferred tax assets	—			10,566
Other current assets	69,612			33,614
Total current assets	829,218			747,851
Long-term investments in marketable securities	9,221			8,677
Long-term restricted cash	16,481			22,113
Property, plant and equipment, net of accumulated depreciation of $143,206 and $130,029	164,521			155,608
Intangible assets, net of accumulated amortization of $44,997 and $36,849	60,777			35,943
Goodwill	257,281			145,607
Deferred tax assets	18,125			6,719
Long-term inventories	54,402			47,109
Other assets, net	22,968			180,222
Total Assets	$	1,432,994		$	1,349,849
Liabilities and Shareholders’ Equity
Current Liabilities:
Accounts payable	$	53,141		$	58,708
Accrued payroll liabilities	40,131			38,643
Accrued warranty reserves	15,796			14,107
Deferred revenue	115,076			101,155
Income taxes payable	10,290			12,124
Accrued restructuring and reorganization	432			655
Other current liabilities	61,434			52,630
Total current liabilities	296,300			278,022
Long-term deferred revenue	46,397			44,745
Other liabilities	47,404			37,006
Commitments and contingencies
Shareholders’ Equity:
Preferred stock - 500 shares authorized; none issued and outstanding	—			—
Common stock - 70,000 shares authorized; 41,016 and 40,855 shares issued and outstanding, no par value	547,901			533,062
Retained earnings	560,757			538,053
Accumulated other comprehensive loss	(65,765		)	(81,039		)
Total Shareholders’ Equity	1,042,893			990,076
Total Liabilities and Shareholders’ Equity	$	1,432,994		$	1,349,849

See accompanying Condensed Notes to the Consolidated Financial Statements.

2

FEI Company and Subsidiaries

Consolidated Statements of Operations

(In thousands, except per share amounts)

(Unaudited)

	Thirteen Weeks Ended						Twenty-Six Weeks Ended
	July 3, 2016			June 28, 2015			July 3, 2016			June 28, 2015
Net sales:
Products	$	191,161		$	163,585		$	353,439		$	327,644
Service	68,204			60,604			134,570			117,361
Total net sales	259,365			224,189			488,009			445,005
Cost of sales:
Products	93,645			78,825			176,310			160,326
Service	39,275			33,259			77,982			67,303
Total cost of sales	132,920			112,084			254,292			227,629
Gross profit	126,445			112,105			233,717			217,376
Operating expenses:
Research and development	29,968			23,128			57,613			46,450
Selling, general and administrative	64,117			43,093			113,356			88,915
Restructuring and reorganization	—			(21		)	(102		)	(142		)
Total operating expenses	94,085			66,200			170,867			135,223
Operating income	32,360			45,905			62,850			82,153
Other expense:
Interest income	199			254			383			465
Interest expense	(349		)	(140		)	(803		)	(234		)
Other, net	(1,016		)	(704		)	(1,837		)	(1,788		)
Total other expense, net	(1,166		)	(590		)	(2,257		)	(1,557		)
Income before income taxes	31,194			45,315			60,593			80,596
Income tax expense	6,254			7,983			12,751			15,252
Net income	$	24,940		$	37,332		$	47,842		$	65,344
Basic net income per share	$	0.61		$	0.90		$	1.17		$	1.57
Diluted net income per share	$	0.60		$	0.89		$	1.16		$	1.55
Cash dividends declared per share	$	0.30		$	0.30		$	0.60		$	0.55
Shares used in per share calculations:
Basic	40,922			41,629			40,890			41,711
Diluted	41,389			42,044			41,304			42,142

See accompanying Condensed Notes to the Consolidated Financial Statements.

3

FEI Company and Subsidiaries

Consolidated Statements of Comprehensive Income

(In thousands)

(Unaudited)

	Thirteen Weeks Ended						Twenty-Six Weeks Ended
	July 3, 2016			June 28, 2015			July 3, 2016			June 28, 2015
Net income	$	24,940		$	37,332		$	47,842		$	65,344
Other comprehensive income, net of taxes:
Change in cumulative translation adjustment	(14,163		)	15,605			14,869			(39,024		)
Change in unrealized (loss) gain on available-for-sale securities	—			(7		)	—			48
Change in minimum pension liability	35			(18		)	8			71
Changes due to cash flow hedging instruments:
Net loss on hedge instruments	(2,308		)	(1,316		)	(1,684		)	(5,108		)
Reclassification to net income of previously deferred losses related to hedge derivatives instruments	1,059			3,099			2,081			5,867
Comprehensive income	$	9,563		$	54,695		$	63,116		$	27,198

See accompanying Condensed Notes to the Consolidated Financial Statements.

4

FEI Company and Subsidiaries

Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

	Twenty-Six Weeks Ended
	July 3, 2016			June 28, 2015
Cash flows from operating activities:
Net income	$	47,842		$	65,344
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	13,681			12,063
Amortization	7,657			5,715
Stock-based compensation	11,869			10,494
Gain (loss) on disposals of property, plant and equipment and other	2			(116		)
Income taxes (receivable) payable, net	(15,972		)	6,547
Deferred income taxes	(2,790		)	(4,785		)
Decrease (increase), net of acquisitions, in:
Receivables, net	(6,003		)	9,980
Inventories	(7,466		)	(19,942		)
Other assets	(16,861		)	4,329
Increase (decrease), net of acquisitions, in:
Accounts payable	(7,747		)	218
Accrued payroll liabilities	(2,184		)	584
Accrued warranty reserves	676			590
Deferred revenue	8,243			6,412
Accrued restructuring and reorganization	(235		)	(6,894		)
Other liabilities	(1,213		)	(1,555		)
Net cash provided by operating activities	29,499			88,984
Cash flows from investing activities:
Decrease in restricted cash	17,507			4,392
Acquisition of property, plant and equipment	(10,790		)	(7,869		)
Payments for acquisitions, net of cash acquired	—			(5,377		)
Purchase of investments in marketable securities	—			(48,240		)
Redemption of investments in marketable securities	—			62,679
Other	(493		)	(1,772		)
Net cash provided by investing activities	6,224			3,813
Cash flows from financing activities:
Dividends paid on common stock	(24,518		)	(20,877		)
Withholding taxes paid on issuance of vested restricted stock units	(3,445		)	(2,427		)
Proceeds from exercise of stock options and employee stock purchases	5,895			7,873
Excess tax benefit for share based payment arrangements	308			879
Repurchases of common stock	(943		)	(30,224		)
Net cash used in financing activities	(22,703		)	(44,776		)
Effect of exchange rate changes	3,414			(15,334		)
Increase in cash and cash equivalents	16,434			32,687
Cash and cash equivalents:
Beginning of period	300,911			300,507
End of period	$	317,345		$	333,194
Supplemental Cash Flow Information:
Cash paid for income taxes, net	$	29,197		$	10,597
Cash paid for interest	694			145
Increase in fixed assets related to transfers from inventories	7,407			4,077
Dividends declared but not paid	12,305			12,479
Accrued purchases of plant and equipment	791			443
Accrued repurchases of common stock	—			1,271

See accompanying Condensed Notes to the Consolidated Financial Statements.

5

FEI COMPANY AND SUBSIDIARIES

CONDENSED NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1. ORGANIZATION AND BASIS OF PRESENTATION

Nature of Business

We are a leading supplier of scientific instruments and related services for nanoscale applications and solutions for industry and science.

We enable customers to find meaningful answers to questions that accelerate breakthrough discoveries, increase productivity, and ultimately change the world. We design, manufacture, and support the broadest range of high-performance microscopy workflows that provide images and answers in the micro-, nano-, and picometer scales. Combining hardware and software expertise in electron, ion, and light microscopy with deep application knowledge in the materials science, life sciences, semiconductor, and oil & gas markets, we are dedicated to our customers’ pursuit of discovery and resolution to global challenges.

We report our revenue based on a group structure organization, which we categorize as the Industry Group and the Science Group.

Our significant research and development and manufacturing operations are located in Hillsboro, Oregon; Eindhoven, The Netherlands; and Brno, Czech Republic; and our software development is managed principally from Bordeaux, France. Our sales and service operations are conducted in the United States (“U.S.”) and approximately50other countries around the world. We also sell our products through independent agents, distributors and representatives in additional countries.

Basis of Presentation

The consolidated financial statements include the accounts of FEI Company and our wholly-owned subsidiaries (collectively, “FEI”). All significant intercompany balances and transactions have been eliminated in consolidation.

The accompanying consolidated financial statements and condensed footnotes have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments considered necessary for fair presentation have been included. The results of operations for the thirteen week period ended July 3, 2016 are not necessarily indicative of the results to be expected for the full year. For further information, refer to the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2015, which was filed with the Securities and Exchange Commission on February 22, 2016.

Use of Estimates in Financial Reporting

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period.

Significant accounting policies and estimates underlying the accompanying consolidated financial statements include:

• the timing of revenue recognition;

• valuations of excess and obsolete inventory;

• the lives and recoverability of equipment and other long-lived assets;

• the valuation of goodwill;

• restructuring and reorganization costs;

• tax valuation allowances and unrecognized tax benefits;

• stock-based compensation; and

• accounting for derivatives.

It is reasonably possible that management’s estimates may change in the future.

6

Merger Agreement

On May 26, 2016, we entered into a definitive agreement to be acquired by Thermo Fisher Scientific Inc. (“Thermo Fisher”) for $107.50 in cash for each share of our common stock (the “Merger”). Completion of the Merger is subject to the satisfaction of various conditions, including approval of the Merger by our shareholders, the absence of certain legal impediments, the absence of a material adverse effect on our business, and the approval of antitrust authorities in China and other foreign jurisdictions.  For more information about the Merger, please see the definitive proxy statement on Schedule 14A we filed with the Securities and Exchange Commission on July 27, 2016.

NOTE 2.    NEW ACCOUNTING PRONOUNCEMENTS

ASU 2016-12

In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients. The amendments in this update do not change the core principle of the guidance in ASU 2014-09. Rather, the amendments in this update affect only certain narrow aspects of ASU 2014-09. The effective date and transition requirements for the amendments in this ASU are the same as the effective date and transition requirements in ASU 2014-09, Revenue from Contracts with Customers (and any other topic amended by that update). We are evaluating the effect that this standard will have on our consolidated financial statements and related disclosures.

ASU 2016-10

In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing. This ASU addresses certain implementation issues that have surfaced since the issuance of ASU No. 2014-09 in May 2014. The ASU provides guidance in identifying performance obligations and determining the appropriate accounting for licensing arrangements. The effective date and transition requirements for the amendments in this ASU are the same as the effective date and transition requirements in ASU 2014-09(and any other topic amended by that update). We are evaluating the effect that this standard will have on our consolidated financial statements and related disclosures.

ASU 2016-09

In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting. The amendment simplifies several aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The amendment is effective for fiscal years beginning after December 15, 2016 with early application permitted, including interim reporting periods within that reporting period, and the new standard will become effective for us on January 1, 2017. We are evaluating the effect that this standard will have on our consolidated financial statements and related disclosures.

ASU 2016-02

In February 2016, the FASB issued ASU No. 2016-02, Leases. The amendment improves transparency and comparability among companies by recognizing lease assets and lease liabilities on the balance sheet and by disclosing key information about leasing arrangements. The amendment is effective for fiscal years beginning after December 15, 2018 with early application permitted, including interim reporting periods within that reporting period, and the new standard will become effective for us on January 1, 2019. We are evaluating the effect that this standard will have on our consolidated financial statements and related disclosures.

ASU 2015-17

In November 2015, the FASB issued ASU No. 2015-17, Income Taxes: Balance Sheet Classification of Deferred Taxes, which requires presentation of deferred tax assets and liabilities as noncurrent in a classified balance sheet. Early application is permitted for periods beginning after December 15, 2015, including interim reporting periods within that reporting period. The amendments in this update may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. We early-adopted the ASU on a prospective basis as of January 1, 2016 and the statement of financial position as of July 3, 2016 reflects the revised classification of current deferred tax assets and liabilities as noncurrent. Adoption of the ASU resulted in an immaterial reclassification between current deferred tax assets and liabilities and non-current deferred tax assets and liabilities. There was no impact on balances in prior periods. There is no other impact on our consolidated financial statements for early-adopting the ASU.

ASU 2015-16

In September 2015, the FASB issued ASU No. 2015-16, Business Combinations: Simplifying the Accounting for Measurement-Period Adjustments. The amendment requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. It also requires that the acquirer record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at

7

the acquisition date. It eliminates the requirement to retrospectively account for those adjustments. We adopted the ASU on January 1, 2016 however there was no significant impact on our current and previously issued consolidated financial statements.

ASU 2015-11

In July 2015, the FASB issued ASU No. 2015-11, Inventory: Simplifying the Measurement of Inventory. An entity using an inventory method other than last-in, first out (“LIFO”) or the retail inventory method should measure inventory at the lower of cost and net realizable value. The new guidance clarifies that net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Early application is permitted for periods beginning after December 15, 2016, including interim reporting periods within that reporting period, and the new standard will become effective for us on January 1, 2017. We are evaluating the effect that this standard will have on our consolidated financial statements and related disclosures.

ASU 2014-09

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date. Early application is permitted for periods beginning after December 15, 2016, including interim reporting periods within that reporting period, and the new standard will become effective for us on January 1, 2018. The standard permits the use of either the retrospective or cumulative effect transition method. We are evaluating the effect that this standard will have on our consolidated financial statements and related disclosures. We have not yet selected a transition method nor have we determined the effect of the standard on our ongoing financial reporting.

NOTE 3. EARNINGS PER SHARE

Following is a reconciliation of basic earnings per share (“EPS”) and diluted EPS (in thousands, except per share amounts):

	Thirteen Weeks Ended						Thirteen Weeks Ended
	July 3, 2016						June 28, 2015
	Net Income		Shares	Per Share Amount			Net Income		Shares	Per Share Amount
Basic EPS	$	24,940	40,922	$	0.61		$	37,332	41,629	$	0.90
Dilutive effect of stock options, restricted stock units, and shares issuable to Philips	—		467	(0.01		)	—		415	(0.01		)
Diluted EPS	$	24,940	41,389	$	0.60		$	37,332	42,044	$	0.89

	Twenty-Six Weeks Ended						Twenty-Six Weeks Ended
	July 3, 2016						June 28, 2015
	Net Income		Shares	Per Share Amount			Net Income		Shares	Per Share Amount
Basic EPS	$	47,842	40,890	$	1.17		$	65,344	41,711	$	1.57
Dilutive effect of stock options, restricted stock units, and shares issuable to Philips	—		414	(0.01		)	—		431	(0.02		)
Diluted EPS	$	47,842	41,304	$	1.16		$	65,344	42,142	$	1.55

The following table sets forth the schedule of anti-dilutive securities excluded from the computation of diluted EPS (number of shares, in thousands):

	Thirteen Weeks Ended		Twenty-Six Weeks Ended
	July 3, 2016	June 28, 2015	July 3, 2016	June 28, 2015
Stock options	13	474	461	416
Restricted stock units	1	184	5	14

8

NOTE 4. STOCK-BASED COMPENSATION

Employee Share Purchase Plan

As of July 3, 2016, there are 4,450,000 shares of our common stock reserved for issuance under our Employee Share Purchase Plan.

1995 Stock Incentive Plan

At our 2016 Annual Meeting of Shareholders, our shareholders approved an amendment to our 1995 Stock Incentive Plan (the “1995 Plan”) to increase the number of shares of our common stock reserved for issuance under the plan from 11,500,000 to 11,750,000.

The following table sets forth certain information regarding the 1995 Plan:

	July 3, 2016
Shares available for grant	1,612,198
Shares of common stock reserved for issuance pursuant to outstanding exercisable securities	3,249,379

The following table sets forth certain information regarding all options outstanding and exercisable:

	July 3, 2016
	Options Outstanding			Options Exercisable
Number	873,014			435,588
Weighted average exercise price	$	72.04		$	64.59
Aggregate intrinsic value	$	30.5	million	$	18.5	million
Weighted average remaining contractual term	4.7 years			4.0 years

The following table sets forth certain information regarding all RSUs nonvested and expected to vest:

	July 3, 2016
	RSUs Unvested			RSUs Expected to Vest
Number	764,167			651,455
Weighted average grant date per share fair value	$	81.45		$	81.24
Aggregate intrinsic value	$	81.8	million	$	69.7	million
Weighted average remaining term to vest	1.9 years			1.9 years

As of July 3, 2016, unrecognized stock-based compensation related to outstanding, but unvested stock options and RSUs was $58.3 million, which will be recognized over the weighted average remaining vesting period of 2.0 years.

Stock-Based Compensation Expense

Our stock-based compensation expense was included in our consolidated statements of operations as follows (in thousands):

	Thirteen Weeks Ended				Twenty-Six Weeks Ended
	July 3, 2016		June 28, 2015		July 3, 2016		June 28, 2015
Cost of sales	$	944	$	797	$	1,831	$	1,589
Research and development	840		659		1,619		1,289
Selling, general and administrative	4,246		3,089		8,419		7,616
Total stock-based compensation	$	6,030	$	4,545	$	11,869	$	10,494

9

NOTE 5. CREDIT FACILITIES AND RESTRICTED CASH

Multibank Credit Agreement

We have a credit agreement (the “Credit Agreement”), by and among FEI Company, FEI Electron Optics International B.V. (“FEI International”), FEI Electron Optics B.V. (“FEI Electron Optics”, and collectively with FEI Company and FEI International, the “Borrowers”) and DCG Systems, Inc., as Guarantor, the Lenders listed on the signature pages thereof (the “Lenders”) and JPMorgan Chase Bank, N.A., as Administrative Agent (“Agent”). The Credit Agreement provides for a $200.0 million unsecured revolving credit facility, including a $100.0 million subfacility for loans in euros, a $10.0 million subfacility for swingline loans and a $50.0 million subfacility for the issuance of letters of credit. We may, upon notice to Agent, request to increase the revolving loan commitments by an aggregate amount of up to $200.0 million with new or additional commitments subject only to the consent of the Lenders providing the new or additional commitments, for a total unsecured credit facility of up to $400.0 million. The Credit Agreement provides for financial covenants that require us to maintain a minimum interest coverage ratio and limit the maximum leverage that Borrower can maintain at any one time.

As of July 3, 2016, there were no revolving loans or letters of credit outstanding under the Credit Agreement, we were in compliance with all covenants and we were not in default under the Credit Agreement.

Credit Facility

We have a credit facility agreement (the “Credit Facility”) with HSBC Bank plc (“HSBC”), whereby HSBC has provided us with a revocable, uncommitted credit facility up to an amount of 25.0 million euro. The purpose of this facility is to provide a more efficient means of issuing guarantees to our customers when required by contractual terms. Under the terms of the Credit Facility, when requested, HSBC will issue bank guarantees on behalf of the company and our affiliates. Issuance of the guarantee does not create a liability to the company unless it is called by the customer, at which point we would record a liability for the amount that is due under the guarantee to the bank. As of July 3, 2016, HSBC has issued $13.5 million in guarantees under the Credit Facility and we have no liabilities outstanding under the Credit Facility.

Restricted Cash

As part of our contracts with certain customers, we are required to provide letters of credit or bank guarantees which these customers can draw against in the event we do not perform in accordance with our contractual obligations. Bank guarantees and letters of credit outstanding as of July 3, 2016 were approximately $39.7 million. Restricted cash balances securing bank guarantees that expire within 12 months of the balance sheet date are recorded as a current asset on our consolidated balance sheets. Restricted cash balances securing bank guarantees that expire beyond 12 months from the balance sheet date are recorded as long-term restricted cash on our consolidated balance sheets.

NOTE 6. INVENTORIES

Inventories are stated at the lower of cost or market, with cost determined by standard cost methods, which approximate the first-in, first-out method. Inventory costs include material, labor and manufacturing overhead. Service inventories that exceed the estimated requirements for the next 12 months based on recent usage levels are reported as a long-term asset. Management has established inventory reserves based on estimates of excess and/or obsolete current and non-current inventory.

Inventories consisted of the following (in thousands):

	July 3, 2016		December 31, 2015
Raw materials and assembled parts	$	69,717	$	56,348
Service inventories, estimated current requirements	13,461		11,556
Work-in-process	86,247		75,710
Finished goods	30,879		26,899
Total current inventories	$	200,304	$	170,513
Non-current inventories	$	54,402	$	47,109

10

NOTE 7. GOODWILL AND INTANGIBLE ASSETS

Goodwill

The roll-forward of activity related to our goodwill was as follows (in thousands):

	Twenty-Six Weeks Ended
	July 3, 2016		June 28, 2015
Balance, beginning of period	$	145,607	$	170,773
Goodwill additions	108,002		4,100
Goodwill adjustments	3,672		(6,937		)
Balance, end of period	$	257,281	$	167,936

Goodwill represents the excess of the purchase price over the estimated fair value of the net assets acquired in connection with our acquisitions. Additions to goodwill represent goodwill from acquisitions made during the period. Adjustments to goodwill include translation adjustments resulting from fluctuations in the value of goodwill held in currencies other than U.S. dollars, as well as adjustments made for the finalization of the purchase price allocations.

Acquisition of DCG Systems, Inc.

On December 10, 2015, we acquired 100% of the outstanding shares of DCG Systems, Inc. (“DCG”) for approximately $161.8 million in cash. DCG, with approximately 200 employees and headquarters in Fremont, California, is a leading supplier of electrical fault characterization, localization and editing tools, providing process development, yield ramp and failure analysis applications for a wide range of semiconductor and electronics manufacturers.

The total purchase price of the acquisition was $182.2 million. We incurred $3.3 million in transactional costs during the thirteen week period ended December 31, 2015, which were recorded in selling, general and administrative costs in our consolidated statements of operations. The excess of the purchase price over the fair value of the net assets acquired was $109.2 million, which was recorded as goodwill in the Industry Group and is primarily related to expected future cash flows attributable to the synergies expected to be realized after our acquisition and integration of the acquired electrical fault analysis (“EFA”) business.

The preliminary fair values of the assets acquired and liabilities assumed in the acquisition were recognized as follows (in thousands):

	Purchase Price Allocation
Current assets	$	64,335
Non-current assets	9,930
Deferred tax assets	207
Current liabilities	(23,859		)
Non-current liabilities	(7,889		)
Deferred tax liabilities	(1,244		)
Net tangible assets acquired	41,480
Intangible assets acquired:
Developed technology	10,500
In-process research and development	13,100
Customer relationships	6,900
Backlog	1,000
Total intangible assets acquired	31,500
Goodwill	109,246
Total	$	182,226

11

The acquired intangible assets are being amortized using the following methodologies and over the following estimated useful lives:

Intangible Asset	Amortization Methodology	Estimated Useful Life	Weighted Average Amortization Period
Developed technology	Straight-line	2 - 4 years	3.1 years
In-process research and development	Straight-line	3 years	3.0 years
Customer relationships	Straight-line	10 years	10.0 years
Backlog	Amortized when revenue is recognized	0.5 - 1.5 years	0.8 years
Total intangible assets			4.5 years

The allocation of purchase price consideration to assets and liabilities is not yet finalized. The preliminary allocation of the purchase price was based upon preliminary estimates and assumptions that are subject to change within the measurement period (up to one year from the acquisition date). The primary areas of preliminary purchase price allocation that are not yet finalized are certain tax matters. We are also still in the process of determining how much of the goodwill may be deductible for income tax purposes. In the thirteen week period ended July 3, 2016, we recorded additional deferred tax liabilities of $1.2 million which also resulted in an increase in goodwill.

In the thirteen week period ended July 3, 2016, the acquired business contributed revenue of $20.7 million and net income of $1.2 million to our consolidated financial results. In the twenty-six week period ended July 3, 2016, the acquired business contributed revenue of $34.5 million and net loss of $0.5 million to our consolidated financial results.

No pro forma financial information has been provided for this acquisition as it is not significant compared to our overall consolidated financial position.

Intangible Assets

Patents, trademarks and other acquired intangible assets are amortized using the straight-line method over their estimated useful lives ranging from6 months to 10 years. Customer relationships are amortized using the straight-line method over their estimated useful lives ranging from5 to 10 years. Developed technology is amortized using the straight-line method over the estimated useful life of the related technology ranging from2 to 10 years. In-process research and development costs are amortized using the straight-line method over their estimated useful lives ranging from 3 to 5.5 years.

The gross amount of our acquired intangible assets and the related accumulated amortization was as follows (in thousands):

	July 3, 2016			December 31, 2015
Patents, trademarks and other	$	25,865		$	24,278
Accumulated amortization	(16,436		)	(13,923		)
Net patents, trademarks and other	9,429			10,355
Customer relationships	28,565			21,245
Accumulated amortization	(9,944		)	(8,083		)
Net customer relationships	18,621			13,162
Developed technology	33,093			22,155
Accumulated amortization	(14,118		)	(10,517		)
Net developed technology	18,975			11,638
In-process research and development	15,806			2,669
Accumulated amortization	(2,054		)	(1,881		)
Net in-process research and development	13,752			788
Total intangible assets, net	$	60,777		$	35,943

12

Amortization expense was as follows (in thousands):

	Twenty-Six Weeks Ended
	July 3, 2016		June 28, 2015
Patents, trademarks and other	$	2,292	$	1,904
Customer relationships	1,701		1,332
Developed technology	3,434		1,753
In-process research and development	153		136
Total amortization expense	$	7,580	$	5,125

Expected amortization, without consideration for foreign currency effects, is as follows over the next five years and thereafter (in thousands):

	Patents, Trademarks and Other		Customer Relationships		Developed Technology		In-Process Research and Development		Total
Remainder of 2016	$	1,106	$	1,716	$	3,513	$	153	$	6,488
2017	2,918		3,086		5,543		2,682		14,229
2018	2,133		3,002		2,910		4,367		12,412
2019	2,033		2,609		2,910		4,367		11,919
2020	1,215		2,295		1,535		2,183		7,228
Thereafter	24		5,913		2,564		—		8,501
Total future amortization expense	$	9,429	$	18,621	$	18,975	$	13,752	$	60,777

NOTE 8. WARRANTY RESERVES

Our products generally carry a one-year warranty. A reserve is established at the time of sale to cover estimated warranty costs and certain commitments for product upgrades as a component of cost of sales on our consolidated statements of operations. Our estimate of warranty cost is primarily based on our history of warranty repairs and maintenance, as applied to systems currently under warranty. For our new products without a history of known warranty costs, we estimate the expected costs based on our experience with similar product lines and technology. While most new products are extensions of existing technology, the estimate could change if new products require a significantly different level of repair and maintenance than similar products have required in the past. Our estimated warranty costs are reviewed and updated on a quarterly basis. Changes to the reserve occur as volume, product mix and warranty costs fluctuate.

The following is a summary of warranty reserve activity (in thousands):

	Twenty-Six Weeks Ended
	July 3, 2016			June 28, 2015
Balance, beginning of period	$	14,107		$	13,005
Reductions for warranty costs incurred	(7,023		)	(7,234		)
Warranties issued	8,427			7,809
Translation and changes in estimates	285			(269		)
Balance, end of period	$	15,796		$	13,311

NOTE 9. INCOME TAXES

Our tax provision for the thirteen and twenty-six week periods ended July 3, 2016 consisted of taxes accrued in the U.S. and foreign jurisdictions. We continue to record a valuation allowance against a portion of our U.S. and foreign deferred tax assets as we do not believe it is more likely than not that we will be able to utilize the deferred tax assets in future periods.

13

Deferred Income Taxes

Net deferred tax assetswere classified on the balance sheet as follows (in thousands):

	July 3, 2016			December 31, 2015
Deferred tax assets – current	$	—		$	10,566
Deferred tax assets – non-current	18,125			6,719
Deferred tax liabilities – current	—			(441		)
Deferred tax liabilities – non-current	(5,560		)	(5,187		)
Net deferred tax assets	$	12,565		$	11,657
Valuation allowance	$	3,480		$	3,562

Unrecognized Tax Benefits

During the thirteen and twenty-six week periods ended July 3, 2016, unrecognized tax benefits, interest and penalties increased by $1.7 million and $7.1 million, respectively, primarily due to accruals related to the business we acquired in December 2015 of $1.1 million and $6.3 million, respectively.

We recognize interest and penalties related to unrecognized tax benefits in tax expense.

For our major tax jurisdictions, the following years were open for examination by the tax authorities as ofJuly 3, 2016:

Jurisdiction	Open Tax Years
U.S.	2012 and forward
The Netherlands	2013 and forward
Czech Republic	2013 and forward

NOTE 10. RELATED-PARTY ACTIVITY

Related parties with which we had transactions during the thirteen and twenty-six week periods ended July 3, 2016 were as follows:

• one of the members of our Board of Directors serves on the Board of Directors of Electro Scientific Industries, Inc.;

• one of the members of our Board of Directors serves on the Supervisory Board of TMC BV; and

• our Chief Executive Officer is on the Board of Trustees for the Oregon Health and Science University Foundation.

Transactions with these related parties were as follows (in thousands):

	Thirteen Weeks Ended				Twenty-Six Weeks Ended
Sales to Related Parties	July 3, 2016		June 28, 2015		July 3, 2016		June 28, 2015
Product sales:
Oregon Health and Science University	$	46	$	7	46		19
Electro Scientific Industries, Inc.	—		4		—		19
Total product sales to related parties	46		11		46		38
Service sales:
Oregon Health and Science University	93		74		193		159
Total service sales to related parties	93		74		193		159
Total sales to related parties	$	139	$	85	$	239	$	197
Purchases from Related Parties
TMC BV	$	383	$	647	$	443	$	1,347
Oregon Health and Science University	—		11		6		11
Total purchases from related parties	$	383	$	658	$	449	$	1,358

14

Amounts due from (to) related parties were as follows (in thousands):

	July 3, 2016
TMC BV	$	(430	)
Oregon Health and Science University	1
Due to related parties, net	$	(429	)

NOTE 11. COMMITMENTS AND CONTINGENCIES

From time to time, we may be a party to litigation arising in the ordinary course of business. Currently, we are not a party to any litigation that we believe would have a material adverse effect on our financial position, results of operations or cash flows.

Purchase Obligations

We have commitments under non-cancelable purchase orders, primarily relating to inventory, totaling$89.3 million at July 3, 2016. These commitments expire at various times through the first quarter of 2020.

NOTE 12. SEGMENT INFORMATION

Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision maker is our Chief Executive Officer.

We are organized based on a group structure, which we categorize as the Industry Group and the Science Group.

The following tables summarize various financial amounts for each of our business segments (in thousands):

	Thirteen Weeks Ended				Twenty-Six Weeks Ended
	July 3, 2016		June 28, 2015		July 3, 2016		June 28, 2015
Sales to External Customers:
Industry Group	$	123,167	$	119,580	$	245,118	$	231,480
Science Group	136,198		104,609		242,891		213,525
Total	$	259,365	$	224,189	$	488,009	$	445,005
Gross Profit:
Industry Group	$	65,070	$	64,747	$	125,329	$	121,357
Science Group	61,375		47,358		108,388		96,019
Total	$	126,445	$	112,105	$	233,717	$	217,376

	July 3, 2016		December 31, 2015
Goodwill:
Industry Group	$	170,647	$	60,360
Science Group	86,634		85,247
Total	$	257,281	$	145,607
Total Assets:
Industry Group	$	598,995	$	516,397
Science Group	442,339		488,096
Corporate and Eliminations	391,660		345,356
Total	$	1,432,994	$	1,349,849

Market segment disclosures are presented to the gross profit level as this is the primary performance measure for which the segment general managers are responsible. Selling, general and administrative, research and development and other operating expenses are managed and reported at the corporate level and, because these costs are not directly tied to any individual market segment, they have not been allocated to the market segments. See the consolidated statements of operations for reconciliations from gross profit to income before income taxes. These reconciling items are not included in the measure of profit and loss for each reportable segment.

15

In the thirteen week periods ended July 3, 2016 and June 28, 2015, our top 10 customers accounted for approximately 30% and 38% of our total annual net revenue, respectively. In the twenty-six week periods ended July 3, 2016 and June 28, 2015, our top 10 customers accounted for approximately 29% and 33% of our total annual net revenue, respectively. No single customer accounted for more than 10% of net revenues during the thirteen and twenty-six week periods ended July 3, 2016 and June 28, 2015.

NOTE 13. RESTRUCTURING AND REORGANIZATION

Second Quarter 2014 Realignment

During the second quarter of 2014, we implemented a resource realignment plan (the “Realignment Plan”) aimed at improving our operational efficiency by eliminating redundancies in sites and personnel resulting from recent acquisitions and expansion activities. We also shifted our resources to growing regions, such as Asia, and potential growth markets, such as structural biology, oil and gas, near-line semiconductor processing and metals research, in order to better position us to pursue our growth strategy. The Realignment Plan activities included the consolidation of our three Australia sites in Canberra; the closure of our facility in Delmont, Pennsylvania and relocation of those operations to our new facility in the Czech Republic; relocation of our Japan demonstration facility to our Shanghai facility; selective reductions in staffing, relocations and compensation adjustments related to the foregoing activities and other realignment of management resources. The Realignment Plan was completed at the end of 2014 and we do not expect to incur any additional costs under this plan.

The following table summarizes our restructuring and reorganization expenditures (in thousands):

	Thirteen Weeks Ended					Twenty-Six Weeks Ended
	July 3, 2016		June 28, 2015			July 3, 2016			June 28, 2015
Restructuring and reorganization	$	—	$	(21	)	$	(102	)	$	(142	)
Total	$	—	$	(21	)	$	(102	)	$	(142	)

Restructuring and Reorganization Accrual

The following table summarizes the charges, expenditures, write-offs and adjustments related to our restructuring and reorganization accrual (in thousands):

	Twenty-Six Weeks Ended
Realignment Plan	July 3, 2016			June 28, 2015
Beginning accrued liability	$	655		$	9,161
Charged to expense, net	(102		)	(142		)
Expenditures	(145		)	(6,750		)
Write-offs and adjustments	24			(577		)
Ending accrued liability	$	432		$	1,692

NOTE 14. FAIR VALUE MEASUREMENTS OF ASSETS AND LIABILITIES

Factors used in determining the fair value of our financial assets and liabilities are summarized into three broad categories:

• Level 1 – quoted prices in active markets for identical securities as of the reporting date;

• Level 2 – other significant directly or indirectly observable inputs, including quoted prices for similar securities, interest rates, prepayment speeds and credit risk; and

• Level 3 – significant inputs that are generally less observable than objective sources, including our own assumptions in determining fair value.

The factors or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

16

Following are the disclosures related to the fair value of our financial assets and (liabilities) (in thousands):

July 3, 2016	Level 1		Level 2		Level 3		Total
Trading securities:
Equity securities – mutual funds	$	9,221	$	—	$	—	$	9,221
Derivative contracts, net	—		1,962		—		1,962
Total	$	9,221	$	1,962	$	—	$	11,183

December 31, 2015	Level 1		Level 2		Level 3		Total
Trading securities:
Equity securities – mutual funds	$	8,677	$	—	$	—	$	8,677
Derivative contracts, net	—		1,013		—		1,013
Total	$	8,677	$	1,013	$	—	$	9,690

We use an income approach to value the assets and liabilities for outstanding derivative contracts using current market information as of the reporting date, such as spot rates, interest rate differentials and implied volatility.

There were no transfers between fair value categories or changes to our valuation techniques during thetwenty-six week periods endedJuly 3, 2016.

We believe the carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and other current liabilities are a reasonable approximation of the fair value of those financial instruments because of the nature of the underlying transactions and the short-term maturities involved.

NOTE 15. DERIVATIVE INSTRUMENTS

In the normal course of business, we are exposed to foreign currency risk and we use derivatives to mitigate financial exposure from movements in foreign currency exchange rates.

The aggregate notional amount of outstanding derivative contracts were as follows (in thousands):

	July 3, 2016		December 31, 2015
Cash flow hedges	$	120,000	$	150,000
Balance sheet hedges	213,727		195,653
Total outstanding derivative contracts	$	333,727	$	345,653

The outstanding contracts at July 3, 2016 have varying maturities through the fourth quarter of 2017. We do not enter into derivative financial instruments for speculative purposes.

We attempt to mitigate derivative credit risk by transacting with highly rated counterparties. We have evaluated the credit and nonperformance risks associated with our derivative counterparties and believe them to be insignificant and not warranting a credit adjustment atJuly 3, 2016. In addition, there are no credit contingent features in our derivative instruments.

Balance Sheet Related

In countries outside of the U.S., we transact business in U.S. dollars and in various other currencies. We attempt to mitigate our currency exposures for recorded transactions by using forward exchange contracts to reduce the risk that our future cash flows will be adversely affected by changes in exchange rates. We enter into forward sale or purchase contracts for foreign currencies to economically hedge specific cash, receivables or payables positions denominated in foreign currencies.

Changes in fair value of derivatives entered into to mitigate the foreign exchange risks related to these balance sheet items are recorded in other income (expense) together with the transaction gain or loss from the respective balance sheet position as follows (in thousands):

	Thirteen Weeks Ended						Twenty-Six Weeks Ended
	July 3, 2016			June 28, 2015			July 3, 2016			June 28, 2015
Foreign currency loss, inclusive of the impact of derivatives	$	(662	)	$	(486	)	$	(1,438	)	$	(606	)

17

Cash Flow Hedges

We use zero cost and net purchased collar contracts and option contracts to hedge certain anticipated foreign currency exchange transactions. The foreign exchange hedging structure may extend, generally, up to a twenty-four month time horizon. The hedging transactions we undertake primarily limit our exposure to changes in the U.S. dollar/euro and the U.S. dollar/Czech koruna exchange rates. The hedges are designed to protect us as the U.S. dollar weakens, but also provide us with some flexibility if the dollar strengthens.

These derivatives meet the criteria to be designated as cash flow hedges and, accordingly, we record the change in fair value of the effective portion of these hedge contracts relating to anticipated transactions in other comprehensive income rather than net income until the underlying hedged transaction affects net income.Gains and losses resulting from the ineffective portion of the hedge contracts, if any, are recognized as a component of net income. Gains and losses related to cash flow derivative contracts not designated as hedging instruments are recorded as a component of net income.

Summary

Our derivative instruments are subject to master netting arrangements and are presented net in our balance sheet. We do not have any financial collateral related to these netting arrangements. The effect of these netting arrangements on our balance sheet is as follows (in thousands):

	Offsetting of Derivative Assets							Offsetting of Derivative Liabilities
July 3, 2016	Gross Amounts of Recognized Assets		Gross Amounts Offset in the Balance Sheet			Net Amounts Presented in Other Current Assets		Gross Amounts of Recognized Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts Presented in Other Current Liabilities
Foreign exchange contracts designated as hedging instruments	$	2,817	$	(855	)	$	1,962	$	—	$	—	$	—
Foreign exchange contracts not designated as hedging instruments	—		—			—		—		—		—
Total	$	2,817	$	(855	)	$	1,962	$	—	$	—	$	—

	Offsetting of Derivative Assets							Offsetting of Derivative Liabilities
December 31, 2015	Gross Amounts of Recognized Assets		Gross Amounts Offset in the Balance Sheet			Net Amounts Presented in Other Current Assets		Gross Amounts of Recognized Liabilities		Gross Amounts Offset in the Balance Sheet			Net Amounts Presented in Other Current Liabilities
Foreign exchange contracts designated as hedging instruments	$	2,908	$	(943	)	$	1,965	$	—	$	—		$	—
Foreign exchange contracts not designated as hedging instruments	545		(238		)	307		1,330		(71		)	1,259
Total	$	3,453	$	(1,181	)	$	2,272	$	1,330	$	(71	)	$	1,259

The effect of derivative instruments was as follows (in thousands):

	Thirteen Weeks Ended						Twenty-Six Weeks Ended
Foreign Exchange Contracts in Cash Flow Hedging Relationships	July 3, 2016			June 28, 2015			July 3, 2016			June 28, 2015
Amount of gain/(loss):
Recognized in AOCI (effective portion)	$	(1,265	)	$	(5,436	)	$	(532	)	$	(13,724	)
Reclassified from AOCI into revenue (effective portion)	—			—			—			(112		)
Reclassified from AOCI into cost of sales (effective portion)	(1,058		)	(3,084		)	(2,080		)	(5,647		)
Recognized in other, net (ineffective portion and amount excluded from effectiveness testing)	(1		)	(15		)	(1		)	(108		)
Foreign Exchange Contracts Not in Cash Flow Hedging Relationships
Amount of gain/(loss):
Recognized in other, net	$	(1,965	)	$	1,473		$	22		$	(5,685	)

The unrealized losses at July 3, 2016 are expected to be reclassified to net income during the next sixteen months as a result of the underlying hedged transactions also being recorded in net income.

18

NOTE 16. CHANGES IN ACCUMULATED OTHER COMPREHENSIVE INCOME

The following tables illustrate the disclosure of changes in the balances of each component of accumulated other comprehensive income (“AOCI”), as well as details the effect of reclassifications out of AOCI on the line items in our consolidated statements of operations by component (net of tax, in thousands):

	Thirteen Weeks Ended July 3, 2016
	Foreign Currency Items			Unrealized Gains and Losses on Available-for-Sale Securities		Defined Benefit Pension Items			Gains and Losses on Cash Flow Hedges			Total
Beginning Balance	$	(50,213	)	$	2	$	(636	)	$	459		$	(50,388	)
Other comprehensive income before reclassifications	(14,163		)	—		35			(2,308		)	(16,436		)
Amounts reclassified from AOCI to:
Cost of goods sold	—			—		—			1,058			1,058
Other, net	—			—		—			1			1
Total reclassifications out of AOCI	—			—		—			1,059			1,059
Net current period other comprehensive income	(14,163		)	—		35			(1,249		)	(15,377		)
Ending balance	$	(64,376	)	$	2	$	(601	)	$	(790	)	$	(65,765	)

	Thirteen Weeks Ended June 28, 2015
	Foreign Currency Items			Unrealized Gains and Losses on Available-for-Sale Securities			Defined Benefit Pension Items			Gains and Losses on Cash Flow Hedges			Total
Beginning Balance	$	(77,170	)	$	17		$	(709	)	$	(5,158	)	$	(83,020	)
Other comprehensive income before reclassifications	15,605			(7		)	(18		)	(1,316		)	14,264
Amounts reclassified from AOCI to:
Cost of goods sold	—			—			—			3,084			3,084
Other, net	—			—			—			15			15
Total reclassifications out of AOCI	—			—			—			3,099			3,099
Net current period other comprehensive income	15,605			(7		)	(18		)	1,783			17,363
Ending balance	$	(61,565	)	$	10		$	(727	)	$	(3,375	)	$	(65,657	)

19

	Twenty-Six Weeks Ended July 3, 2016
	Foreign Currency Items			Unrealized Gains and Losses on Available-for-Sale Securities		Defined Benefit Pension Items			Gains and Losses on Cash Flow Hedges			Total
Beginning Balance	$	(79,245	)	$	2	$	(609	)	$	(1,187	)	$	(81,039	)
Other comprehensive income before reclassifications	14,869			—		8			(1,684		)	13,193
Amounts reclassified from AOCI to:
Cost of goods sold	—			—		—			2,080			2,080
Other, net	—			—		—			1			1
Total reclassifications out of AOCI	—			—		—			2,081			2,081
Net current period other comprehensive income	14,869			—		8			397			15,274
Ending balance	$	(64,376	)	$	2	$	(601	)	$	(790	)	$	(65,765	)

	Twenty-Six Weeks Ended June 28, 2015
	Foreign Currency Items			Unrealized Gains and Losses on Available-for-Sale Securities			Defined Benefit Pension Items			Gains and Losses on Cash Flow Hedges			Total
Beginning Balance	$	(22,541	)	$	(38	)	$	(798	)	$	(4,134	)	$	(27,511	)
Other comprehensive income before reclassifications	(39,024		)	48			71			(5,108		)	(44,013		)
Amounts reclassified from AOCI to:
Revenue	—			—			—			112			112
Cost of goods sold	—			—			—			5,647			5,647
Other, net	—			—			—			108			108
Total reclassifications out of AOCI	—			—			—			5,867			5,867
Net current period other comprehensive income	(39,024		)	48			71			759			(38,146		)
Ending balance	$	(61,565	)	$	10		$	(727	)	$	(3,375	)	$	(65,657	)

NOTE 17. FACTORING OF ACCOUNTS RECEIVABLE

We entered into agreements under which we sold a total of $1.2 million and $2.6 million of our accounts receivable at a discount to unrelated third party financiers without recourse during the thirteen week periods ended July 3, 2016 and June 28, 2015, respectively. We sold a total of $14.1 million and $2.6 million of our accounts receivable at a discount to unrelated third party financiers without recourse during the twenty-six week periods ended July 3, 2016 and June 28, 2015, respectively. The transfers qualified for sales treatment and, accordingly, discounts related to the sale of the receivables, which were immaterial, were recorded on our consolidated statements of operations as other expense.

20

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements, including statements regarding our pending acquisition by Thermo Fisher Scientific Inc., sources of revenue, our investments and expenditures, our effective tax rate, the location of our cash and cash equivalents, the level of profitability at which we expect to operate and the allocation of our resources and expenditures. Forward-looking statements may also be identified by words and phrases that refer to future expectations, such as “guidance”, “guiding”, “forecast”, “toward”, “plan”, “expect”, “are expected”, “is expected”, “believe”, “anticipate”, “estimate”, “will”, “projecting”, “look forward”, “continue to see”, “outlook” and other similar words and phrases. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could affect such forward-looking statements include, but are not limited to, those discussed in the section titled “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q and from time to time in our other public filings. All forward-looking statements included in this Quarterly Report on Form 10-Q are based on information available to us as of the date of this report, and we assume no obligation to update these forward-looking statements.

Summary of Products and Segments

We are a leading supplier of scientific instruments and related services for nanoscale applications and solutions for industry and science.

We enable customers to find meaningful answers to questions that accelerate breakthrough discoveries, increase productivity, and ultimately change the world. We design, manufacture, and support the broadest range of high-performance microscopy workflows that provide images and answers in the micro-, nano-, and picometer scales. Combining hardware and software expertise in electron, ion, and light microscopy with deep application knowledge in the materials science, life sciences, semiconductor, and oil & gas markets, we are dedicated to our customers’ pursuit of discovery and resolution to global challenges.

We are organized based on a group structure, which we categorize as the Industry Group and the Science Group.

The Industry Group consists of customers in semiconductor integrated circuit manufacturing and related industries such as manufacturers of data storage equipment and other technologies, as well as customers in the oil and gas industry. The tools we develop for our Industry Group customers are generally aimed at improving their processes to increase overall yields, whether in a semiconductor factory or at an oil and gas reservoir. For the semiconductor market, our growth is driven by shrinking line widths and process nodes of 16/14 nanometers and smaller, increasing complexity in their materials such as high-k metal gates and low-k dielectrics and increasing device complexity such as 3D transistor architectures. Such products are used primarily in laboratories, near the fabrication line to speed new product development and increase yields by enabling 3D metrology for advanced process control, defect analysis, and root cause failure analysis. For the oil and gas market, our products are used to increase yields in oil and gas exploration and for laboratory analysis. We also provide support for products and customers within this group for the entire life cycle of a tool from installation through the warranty period, and after the warranty period through contract coverage or on a time and materials basis.

The Science Group includes universities, public and private research laboratories and customers in a wide range of industries, including metals, automobiles, aerospace, geosciences and forensics. The tools we develop for our customers in the Science Group are generally aimed at the exploration and discovery of new materials and chemistries or solving for causes and cures of diseases. The tools are used in a laboratory and are generally not used in industrial applications. The Science Group also includes customers at universities, government laboratories and research institutes engaged in biotech and life sciences applications, as well as pharmaceutical and biotech companies. Growth in these markets is driven by global corporate and government funding for research and development and by development of new products and processes based on innovations at the nanoscale. Our solutions enable scientific discovery and advancement for researchers and help manufacturers develop, analyze and produce advanced products. Our products are also used in root cause failure analysis and quality control applications across a range of industries. Our products’ ultra-high resolution imaging allows structural biologists to create detailed 3D reconstructions of complex biological structures such as proteins and viruses. Cellular biologists use our tools to correlate wide-field, lower resolution optical images with higher resolution electron microscope imaging. Our products are also used by drug researchers and in particle analysis and a range of pathology and quality control applications. We also provide support for products and customers within this group for the entire life cycle of a tool from installation through the warranty period, and after the warranty period through contract coverage or on a time and materials basis.

21

On May 26, 2016, we entered into a definitive agreement to be acquired by Thermo Fisher Scientific Inc. (“Thermo Fisher”) for $107.50 in cash for each share of our common stock (the “Merger”). Completion of the Merger is subject to the satisfaction of various conditions, including approval of the Merger by our shareholders, the absence of certain legal impediments, the absence of a material adverse effect on our business, and the approval of antitrust authorities in China and other foreign jurisdictions.  For more information about the Merger, please see the definitive proxy statement on Schedule 14A we filed with the Securities and Exchange Commission on July 27, 2016.

Backlog Overview

Customer orders that have been received but not yet recognized as revenue in a particular period are reported as backlog. We only recognize backlog for purchase commitments for which the terms of the sale have been agreed upon, including price, configuration, options and payment terms. Purchase commitments may include letters of intent. Product backlog consists of all open orders meeting these criteria. Service backlog consists of open orders for service, unearned revenue on service contracts and open orders for spare parts. U.S. government backlog is limited to contracted amounts. In addition, some of the U.S. government backlog may represent uncommitted funds.

At July 3, 2016 our total backlog was $651.1 million, compared to $590.6 million in total backlog at December 31, 2015.

We estimate that currently, 85% to 90% of our backlog will be recognized as revenue within one year.

Historically, our cancellations have been low. During the twenty-six week periods ended July 3, 2016 and June 28, 2015, we experienced cancellations of $8.9 million and $5.2 million, respectively.

Critical Accounting Policies and the Use of Estimates

Preparation of our financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Management bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Management’s Discussion and Analysis and Note 1 to the Consolidated Financial Statements in our 2015Annual Report on Form 10-K describe the significant accounting estimates and policies used in preparation of the Consolidated Financial Statements. Actual results in these areas could differ from management’s estimates. During the twenty-six week period ended July 3, 2016, there were no significant changes in our critical accounting policies or estimates from those reported in our Annual Report on Form 10-K for the year ended December 31, 2015, which was filed with the Securities and Exchange Commission on February 22, 2016.

Results of Operations

The following tables set forth our statement of operations data, in absolute dollars and as a percentage⁽¹⁾of consolidated net sales (dollars in thousands):

	Thirteen Weeks Ended
	July 3, 2016					June 28, 2015
Net sales	$	259,365		100.0	%	$	224,189		100.0	%
Cost of sales	132,920			51.2		112,084			50.0
Gross profit	126,445			48.8		112,105			50.0
Research and development	29,968			11.6		23,128			10.3
Selling, general and administrative	64,117			24.7		43,093			19.2
Restructuring and reorganization	—			—		(21		)	—
Operating income	32,360			12.5		45,905			20.5
Other expense, net	(1,166		)	(0.4	)	(590		)	(0.3	)
Income before income taxes	31,194			12.0		45,315			20.2
Income tax expense	6,254			2.4		7,983			3.6
Net income	$	24,940		9.6	%	$	37,332		16.7	%

22

	Twenty-Six Weeks Ended
	July 3, 2016					June 28, 2015
Net sales	$	488,009		100.0	%	$	445,005		100.0	%
Cost of sales	254,292			52.1		227,629			51.2
Gross profit	233,717			47.9		217,376			48.8
Research and development	57,613			11.8		46,450			10.4
Selling, general and administrative	113,356			23.2		88,915			20.0
Restructuring and reorganization	(102		)	—		(142		)	—
Operating income	62,850			12.9		82,153			18.5
Other expense, net	(2,257		)	(0.5	)	(1,557		)	(0.3	)
Income before income taxes	60,593			12.4		80,596			18.1
Income tax expense	12,751			2.6		15,252			3.4
Net income	$	47,842		9.8	%	$	65,344		14.7	%

⁽¹⁾  Percentages may not add due to rounding.

Net Sales Overview

Net sales increased$35.2 million, or 15.7%, to $259.4 million in the thirteen week period endedJuly 3, 2016 (the second quarter of 2016) compared to $224.2 million in the thirteen week period endedJune 28, 2015 (the second quarter of 2015). Revenue from our recently acquired business increased net sales by $20.7 million, or 9.2%, in the thirteen week period endedJuly 3, 2016 compared to the same period of 2015.

Net sales increased $43.0 million, or 9.7%, to $488.0 million in the twenty-six week period ended July 3, 2016 compared to $445.0 million in the twenty-six week period ended June 28, 2015. Revenue from our recently acquired business increased net sales by $34.5 million, or 7.8%, in the twenty-six week period ended July 3, 2016 compared to the same period of 2015.

Net sales, at consistent currency rates, increased $34.1 million, or 15.2%, and $44.4 million, or 10.0%, in the thirteen and twenty-six week periods ended July 3, 2016 compared to the same periods of 2015, respectively. Consistent currency rates are defined as the quarterly average currency exchange rates in effect for the initial comparable period, applied to both periods. All discussion of changes between the current and comparable periods is based on consistent currency rates.

Strengthening of the U.S. dollar against foreign currencies generally has the effect of decreasing net sales and backlog. See also “Foreign Currency Exchange Rate Risk” included in Part II, Item 1A of this Quarterly Report on Form 10-Q for further discussion of currency impacts on our results of operations.

Other factors affecting net sales are discussed in more detail in the Net Sales by Segment discussion below.

Net Sales by Segment

Net sales by market segment (in thousands) and as a percentage of net sales were as follows:

	Thirteen Weeks Ended
	July 3, 2016				June 28, 2015
Industry Group	$	123,167	47.5	%	$	119,580	53.3	%
Science Group	136,198		52.5		104,609		46.7
Consolidated net sales	$	259,365	100.0	%	$	224,189	100.0	%

	Twenty-Six Weeks Ended
	July 3, 2016				June 28, 2015
Industry Group	$	245,118	50.2	%	$	231,480	52.0	%
Science Group	242,891		49.8		213,525		48.0
Consolidated net sales	$	488,009	100.0	%	$	445,005	100.0	%

23

Industry Group

Industry Group sales increased $3.6 million, or 3.0%, and $13.6 million, or 5.9%, in the thirteen and twenty-six week periods ended July 3, 2016 compared to the same periods of 2015. At consistent currency rates, Industry Group sales increased $3.7 million, or 3.1%, and $14.8 million, or 6.4%, in the thirteen and twenty-six week periods ended July 3, 2016. The increase in both periods was primarily due from the business we acquired in the fourth quarter of 2015 and higher service revenue from our installed base. Increases were partially offset by a decline in sales of high resolution near-line products to semiconductor customers.

Revenue from acquired businesses in our Industry Group increased sales $20.7 million, or 17.3%, and $34.5 million, or 14.9%, in the thirteen and twenty-six week periods ended July 3, 2016, compared to the same periods of 2015.

Science Group

Science Group sales increased $31.6 million, or 30.2%, and $29.4 million, or 13.8%, in the thirteen and twenty-six week periods ended July 3, 2016 compared to the same periods in 2015. At consistent currency rates, Science Group sales increased $30.4 million, or 29.1%, and $29.6 million, or 13.9%, in the thirteen and twenty-six week periods ended July 3, 2016. The increase in both periods was primarily due to more high resolution systems sold to our structural and cell biology customers and higher service revenue from our installed base.

Net Sales by Geographic Region

A majority of our net sales are derived from customers outside of the U.S., which we expect to continue. The following tables show our net sales by geographic region (in thousands):

	Thirteen Weeks Ended
	July 3, 2016				June 28, 2015
U.S. and Canada	$	79,808	30.8	%	$	76,447	34.1	%
Europe	67,991		26.2		56,754		25.3
Asia-Pacific Region and Rest of World	111,566		43.0		90,988		40.6
Consolidated net sales	$	259,365	100.0	%	$	224,189	100.0	%

	Twenty-Six Weeks Ended
	July 3, 2016				June 28, 2015
U.S. and Canada	$	155,134	31.8	%	$	141,364	31.8	%
Europe	129,119		26.4		111,312		25.0
Asia-Pacific Region and Rest of World	203,756		41.8		192,329		43.2
Consolidated net sales	$	488,009	100.0	%	$	445,005	100.0	%

U.S. and Canada

Sales to U.S. and Canada increased $3.4 million, or 4.4%, and $13.8 million, or 9.7%, in the thirteen and twenty-six week periods ended July 3, 2016 compared to the same periods of 2015, respectively. The increase in both periods was primarily due to sales from the business we acquired in December 2015, more sales of high resolution systems sold to our structural and cell biology customers, and higher service revenue from our installed base. Increases were partially offset by a decline in sales to customers involved in materials research.

Europe

Our European region also includes Central America, South America, Africa (excluding South Africa), the Middle East and Russia.

Sales to Europe increased $11.2 million, or 19.8%, and $17.8 million, or 16.0%, in the thirteen and twenty-six week periods ended July 3, 2016 compared to the same periods of 2015, respectively. At consistent currency rates, sales to Europe increased $10.3 million, or 18.1%, and $18.4 million, or 16.5%, in the thirteen and twenty-six week periods ended July 3, 2016, respectively. The increase in both periods was primarily due to an increase in sales of high resolution systems to our structural and cell biology customers and higher service revenue from our installed base. Increases were partially offset by a decline in sales to customer involved in materials research.

Asia-Pacific Region and Rest of World

Sales to the Asia-Pacific Region and Rest of World increased $20.6 million, or 22.6%, and $11.4 million, or 5.9%, in the thirteen and twenty-six week periods ended July 3, 2016 compared to the same periods of 2015, respectively. At consistent currency rates, sales to the Asia-Pacific Region and Rest of World increased $20.4 million, or 22.4%, and $12.1 million, or 6.3%, in the thirteen

24

and twenty-six week periods ended July 3, 2016, respectively. The increase in both periods was primarily due to sales from the business we acquired in December 2015, as well as more sales of high resolution systems to our science customers and higher service revenue from our installed base. Increases were partially offset by fewer systems sold to our semiconductor customers.

Cost of Sales and Gross Margin

Our gross margin (gross profit as a percentage of net sales) by segment was as follows:

	Thirteen Weeks Ended				Twenty-Six Weeks Ended
	July 3, 2016		June 28, 2015		July 3, 2016		June 28, 2015
Industry Group	52.8	%	54.1	%	51.1	%	52.4	%
Science Group	45.1		45.3		44.6		45.0
Overall	48.8		50.0		47.9		48.8

Cost of Sales

Cost of sales includes manufacturing costs, such as materials, labor (both direct and indirect) and factory overhead, as well as all of the costs of our customer service function such as labor, materials, travel and overhead. The four primary drivers affecting gross margin include: product mix, operational efficiencies, competitive pricing pressure and currency movements.

Cost of sales increased$20.8 million, or 18.6%, to $132.9 million in the thirteen week period endedJuly 3, 2016 compared to $112.1 million in the same period of 2015. At consistent currency rates, cost of sales increased $18.7 million, or 16.7%, in the thirteen week period ended July 3, 2016, compared to the same period of 2015.

Cost of sales increased $26.7 million, or 11.7%, to $254.3 million in the twenty-six week period ended July 3, 2016 compared to $227.6 million in the same period of 2015. At consistent currency rates, cost of sales increased $25.7 million, or 11.3%, in the twenty-six week period ended July 3, 2016, compared to the same period of 2015.

Gross Profit and Gross Margin

Gross profit increased $14.3 million, or 12.8%, and $16.3 million, or 7.5%, in the thirteen and twenty-six week periods ended July 3, 2016 compared to the same periods of 2015, respectively. At consistent currency rates, gross profit increased $15.5 million, or 13.8%, and $18.7 million, or 8.6%, in the thirteen and twenty-six week periods ended July 3, 2016, respectively. Gross margin, at consistent currency rates, decreased by 0.6 percentage points in both the thirteen and twenty-six week periods ended July 3, 2016 compared to the same periods of 2015, respectively.

Industry Group

The Industry Group gross margin decreased by 1.3 percentage points during both the thirteen and twenty-six week periods ended July 3, 2016 compared to the same periods of 2015, respectively. At consistent currency rates, Industry Group gross margin decreased by 0.5 and 0.9 percentage points during the thirteen and twenty-six week periods ended July 3, 2016, respectively. In the thirteen week period, the decrease was primarily due to lower margins on systems sold to our semiconductor customers and on service revenue from our installed base. This was partially offset by higher margins on sales from the business we acquired in December 2015. In the twenty-six period, the decrease was primarily due to lower margins from our acquired business as a result of purchase accounting adjustments and lower margins on service revenue from our installed base.

Science Group

The Science Group gross margin decreased by 0.2 and 0.4 percentage points in the thirteen and twenty-six week periods ended July 3, 2016 compared to the same periods of 2015, respectively. At consistent currency rates, Science Group gross margin increased by 0.2 and decreased by 0.1 percentage points during the thirteen and twenty-six week periods ended July 3, 2016, respectively. The change in both periods was due primarily due to higher margins on sales of high resolution systems to our structural and cell biology customers, partially offset by lower margins on sales to customers engaged in materials research as a result of lower average selling prices.

Research and Development Costs

Research and Development (“R&D”) costs include labor, materials, overhead and payments to third parties for research and development of new products and new software or enhancements to existing products and software and are expensed as incurred. We periodically receive funds from various organizations to subsidize our R&D activities. These funds are reported as an offset to R&D expense. During the thirteen and twenty-six week periods ended July 3, 2016, and for the comparable periods in 2015, we received subsidies from European governments for technological developments primarily for semiconductor and life sciences products.

25

R&D costs, net of subsidies, were as follows (in thousands):

	Thirteen Weeks Ended						Twenty-Six Weeks Ended
	July 3, 2016			June 28, 2015			July 3, 2016			June 28, 2015
Gross spending	$	31,528		$	23,916		$	60,396		$	48,018
Less subsidies	(1,560		)	(788		)	(2,783		)	(1,568		)
Net expense	$	29,968		$	23,128		$	57,613		$	46,450

R&D costs increased $6.8 million, or 29.6%, and $11.2 million, or 24.0%, in the thirteen and twenty-six week periods ended July 3, 2016 compared to the same periods of 2015, respectively. At consistent currency rates, R&D costs increased $6.4 million, or 27.7%, and $11.2 million, or 24.1%, in the thirteen and twenty-six week periods ended July 3, 2016, respectively. The increase in both periods was primarily due to higher labor spending and costs from the business we acquired in December 2015.

We anticipate investing between 10% and 11% of revenue in R&D for the foreseeable future. Accordingly, as revenues increase, we expect R&D expenditures will also increase. Actual future spending, however, will depend on market conditions, currency fluctuations and other factors.

See also “Risk Factors” included in Part II, Item 1A of this Quarterly Report on Form 10-Q for further discussion of R&D expense impact on our results of operations.

Selling, General and Administrative Costs

Selling, general and administrative (“SG&A”) costs include labor, travel, outside services and overhead incurred in our sales, marketing, management and administrative support functions. SG&A costs also include sales commissions paid to our employees as well as to our agents.

SG&A costs increased $21.0 million, or 48.8%, and $24.4 million, or 27.5%, in the thirteen and twenty-six week periods ended July 3, 2016 compared to the same periods of 2015, respectively. At consistent currency rates, SG&A costs increased $20.8 million, or 48.3%, and $25.0 million, or 28.1%, in the thirteen and twenty-six week periods ended July 3, 2016, respectively. The increase in both periods was primarily due to consulting and legal costs incurred as a result of the proposed Thermo Fisher acquisition, and integration and SG&A costs for the business we acquired in December 2015.

Restructuring and Reorganization

Second Quarter 2014 Realignment

During the second quarter of 2014, we implemented the Realignment Plan aimed at improving our operational efficiency by eliminating redundancies in sites and personnel resulting from recent acquisitions and expansion activities. We also shifted our resources to growing regions, such as Asia, and potential growth markets, such as structural biology, oil and gas, near-line semiconductor processing and metals research, in order to better position us to pursue our growth strategy. The Realignment Plan activities included the consolidation of our three Australia sites in Canberra; the closure of our facility in Delmont, Pennsylvania and relocation of those operations to our new facility in the Czech Republic; relocation of our Japan demonstration facility to our Shanghai facility; selective reductions in staffing, relocations and compensation adjustments related to the foregoing activities and other realignment of management resources. The Realignment Plan was completed at the end of 2014 and we do not expect to incur any additional costs under this plan.

The following table summarizes our restructuring and reorganization expenditures (in thousands):

	Thirteen Weeks Ended					Twenty-Six Weeks Ended
	July 3, 2016		June 28, 2015			July 3, 2016			June 28, 2015
Restructuring and reorganization	$	—	$	(21	)	$	(102	)	$	(142	)
Total	$	—	$	(21	)	$	(102	)	$	(142	)

Other Expense, Net

Other expense, net includes interest income, interest expense, and other, net which primarily includes foreign currency transaction gains and losses, bank fees and other miscellaneous items.

Changes in other expense, net is primarily due to changes in interest expense which totaled $0.3 million and $0.1 million in the thirteen week periods ended July 3, 2016 and June 28, 2015, respectively, and $0.8 million and $0.2 million in the twenty-six week periods ended July 3, 2016 and June 28, 2015, respectively. Increase in both periods is primarily due to the amortization of fees associated with the Credit Agreement we entered into in the first quarter of 2016.

26

Income Tax Expense

Our income tax expense was $6.3 million and $8.0 million for the thirteen week periods ended July 3, 2016 and June 28, 2015, respectively, and $12.8 million and $15.3 million for the twenty-six week periods ended July 3, 2016 and June 28, 2015, respectively, and reflected taxes accrued in the U.S. and foreign jurisdictions.

Our effective tax rate may differ from the U.S. federal statutory tax rate primarily as a result of the effects of state and foreign income taxes, research and development tax credits earned in the U.S. and foreign jurisdictions, adjustments to our unrecognized tax benefits and our ability or inability to utilize various carry forward tax items. In addition, our effective tax rate may be affected by changes in statutory tax rates and laws in the U.S. and foreign jurisdictions and other factors.

As of July 3, 2016, total unrecognized tax benefits were $24.2 million and related primarily to uncertainty surrounding tax credits, transfer pricing, domestic manufacturing deductions and permanent establishment. All unrecognized tax benefits would decrease the effective tax rate if recognized.

Our net deferred tax assets totaled $12.6 million and $11.7 million at July 3, 2016 and December 31, 2015, respectively. Valuation allowances on deferred tax assets totaled $3.5 million and $3.6 million as of July 3, 2016 and December 31, 2015, respectively. We continue to record a valuation allowance against a portion of U.S. and foreign deferred tax assets, as we do not believe it is more likely than not that we will be able to utilize the deferred tax assets in future periods.

Liquidity and Capital Resources

Sources of Liquidity and Capital Resources

Our sources of liquidity and capital resources consisted of the following (in thousands):

	July 3, 2016		December 31, 2015
Cash and cash equivalents	$	317,345	$	300,911
Restricted cash	8,330		19,119
Total short-term balances	325,675		320,030
Long-term investments in marketable securities	9,221		8,677
Long-term restricted cash	16,481		22,113
Total long-term balances	25,702		30,790
Availability under revolving credit facilities and letters of credit	$	214,381	$	114,739

At July 3, 2016, $294.7 million of our $351.4 million in total cash, cash equivalents, restricted cash and investments, were located outside of the United States. We believe our U.S. sources of cash and liquidity are sufficient to meet our business needs in the U.S. and do not expect that we will need to repatriate the funds we have designated as indefinitely reinvested outside the U.S. Under current tax laws, should our plans change and we were to choose to repatriate some or all of the funds we have designated as indefinitely reinvested outside the U.S., such amounts would be subject to U.S. income taxes and applicable non-U.S. income and withholding taxes. Restricted cash relates to deposits to secure bank guarantees for customer prepayments that expire through 2021.

We believe that we have sufficient cash resources and available credit lines to meet our expected operational and capital needs for at least the next twelve months.

In the twenty-six week period ended July 3, 2016, cash and cash equivalents increased $16.4 million to $317.3 million from $300.9 million as of December 31, 2015 primarily as a result of cash provided by operations of $29.5 million, a decrease in restricted cash of $17.5 million and proceeds from the exercise of employee stock options and employee stock purchases of $5.9 million. These factors were partially offset by dividends paid on common stock of $24.5 million, purchases of property, plant and equipment for $10.8 million and withholding taxes paid on issuance of vested restricted stock units of $3.4 million. Currency fluctuations increased cash and cash equivalents by $3.4 million.

Accounts receivable increased $20.5 million to $233.6 million as of July 3, 2016 compared to $213.1 million as of December 31, 2015. At consistent currency rates, accounts receivable increased $15.8 million from December 31, 2015. This increase was primarily due to the timing of shipments and a decrease in collections on orders recorded as revenue in the last quarter of 2015. Our days sales outstanding, calculated on a quarterly basis, was 82 days and 86 days at July 3, 2016 and June 28, 2015, respectively.

Inventories increased $29.8 million to $200.3 million as of July 3, 2016 compared to $170.5 million as of December 31, 2015. At consistent currency rates, inventories increased $25.5 million from December 31, 2015 mainly due to additional inventory from

27

our recently acquired business and inventory purchases to support our 2016 build plan. Our annualized inventory turnover rate, calculated on a quarterly basis, was 2.1 times and 2.0 times for the quarters ended July 3, 2016 and June 28, 2015, respectively.

Property, plant, and equipment increased $8.9 million to $164.5 million as of July 3, 2016 compared to $155.6 million as of December 31, 2015. At consistent currency rates, property, plant, and equipment increased $7.1 million from December 31, 2015. Expenditures for property, plant and equipment of $10.8 million and transfers from inventories to fixed assets of $7.4 million in the twenty-six week periods ended July 3, 2016 primarily consisted of payments for demonstration equipment and other machinery and equipment, offset by depreciation in the period.

Accounts payable decreased $5.6 million to $53.1 million as of July 3, 2016 compared to $58.7 million as of December 31, 2015. At consistent currency rates, accounts payable decreased $6.8 million from December 31, 2015 primarily due to timing of payments.

Accrued payroll liabilities increased $1.5 million to $40.1 million as of July 3, 2016 compared to $38.6 million as of December 31, 2015. At consistent currency rates, accrued payroll liabilities increased $0.9 million from December 31, 2015 primarily due to increased accruals for employee wages and payroll taxes.

Income taxes payable decreased $1.8 million to $10.3 million as of July 3, 2016 compared to $12.1 million as of December 31, 2015. There was no significant currency impact on income taxes payable. Decrease is due primarily to payments made during the period.

Credit Facilities and Letters of Credit

We have a Credit Agreement with various Lenders and JPMorgan Chase Bank, N.A., as Agent. The Credit Agreement provides for a $200.0 million unsecured revolving credit facility, including a $100.0 million subfacility for loans in euros, a $10.0 million subfacility for swingline loans and a $50.0 million subfacility for the issuance of letters of credit. We may, upon notice to Agent, request to increase the revolving loan commitments by an aggregate amount of up to $200.0 million with new or additional commitments subject only to the consent of the Lenders providing the new or additional commitments, for a total unsecured credit facility of up to $400.0 million. As of July 3, 2016, there were no revolving loans or letters of credit outstanding under the Credit Agreement, and we were in compliance with all covenants under the Credit Agreement. Upon entering into the Credit Agreement, we used cash on hand to pay related fees under our existing $100.0 million secured revolving credit facility and terminated the facility without penalty or premium.

As part of our contracts with certain customers, we are required to provide letters of credit or bank guarantees which these customers can draw against in the event we do not perform in accordance with our contractual obligations. Bank guarantees and letters of credit outstanding as of July 3, 2016 were approximately $39.7 million.

We have a Credit Facility with HSBC, whereby HSBC has provided us with a revocable, uncommitted credit facility up to an amount of 25.0 million euro. The purpose of this facility is to provide a more efficient means of issuing guarantees to our customers when required by contractual terms. Under the terms of the Credit Facility, when requested, HSBC will issue bank guarantees on behalf of the company and our affiliates. Issuance of the guarantee does not create a liability to the company unless it is called by the customer, at which point we would record a liability for the amount that is due under the guarantee to the bank. As of July 3, 2016, HSBC has issued $13.5 million in guarantees under the Credit Facility and we have no liabilities outstanding under the Credit Facility.

We mitigate credit risk by transacting with highly rated counterparties. We have evaluated the credit and non-performance risks associated with our lenders and believe them to be insignificant.

Share Repurchase Plan

In May 2015, our Board of Directors reauthorized our share repurchase program. Under the reauthorization, which expires May 29, 2017, we may repurchase up to 2.0 million shares of our common stock. The amount and timing of specific repurchases are subject to market conditions, applicable legal requirements and other factors. The repurchases are funded from existing cash resources and may be suspended or discontinued at any time at our discretion without prior notice.

The following table sets forth share repurchase information for the periods indicated:

	Thirteen Weeks Ended				Twenty-Six Weeks Ended
	July 3, 2016		June 28, 2015		July 3, 2016		June 28, 2015
Total number of shares repurchased	—		274,646		12,599		408,788
Average price paid per share	$	—	$	77.97	$	74.87	$	77.05
Total value of shares repurchased	$	—	$	21,413,645	$	943,263	$	31,495,231

28

As of July 3, 2016, 922,004 shares remained available for repurchase pursuant to our share repurchase program.

See the section titled “Unregistered Sales of Equity Securities and Use of Proceeds” in Part II, Item 2 of this Quarterly Report on Form 10-Q for further information on our share repurchase program.

Dividends to Shareholders

In June 2012, we announced our plan to initiate a quarterly dividend andour Board of Directors has declared dividends each quarter since the plan’s inception. During the second quarter of 2016, our Board of Directors declared a dividend of $0.30 per share. Dividend payments during the second quarter of 2016 totaled $12.3 million. The declaration and payment of dividends to shareholders in the future is subject to the discretion of our Board of Directors.

New Accounting Pronouncements

See Note 2 of the Condensed Notes to the Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q for a discussion of new accounting pronouncements.

Off-Balance Sheet Arrangements

We have a Credit Facility with HSBC, whereby HSBC has provided us with a revocable, uncommitted credit facility up to an amount of 25.0 million euro. The purpose of this facility is to provide a more efficient means of issuing guarantees to our customers when required by contractual terms. Under the terms of the Credit Facility, when requested, HSBC will issue bank guarantees on behalf of the company and our affiliates. Issuance of the guarantee does not create a liability to the company unless it is called by the customer, at which point we would record a liability for the amount that is due under the guarantee to the bank. As of July 3, 2016, HSBC has issued $13.5 million in guarantees under the Credit Facility and we have no liabilities outstanding under the Credit Facility.

29

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes in our reported market risks and risk management policies since the filing of our2015Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission onFebruary 22, 2016.

We undertake hedging transactions and enter into foreign forward exchange contracts to mitigate the impact of changes in various currency exchange rates. See Note 15 of the Condensed Notes to the Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management evaluated, with the participation and under the supervision of our President and Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures as of the end of the period covered by thisQuarterly Report on Form 10-Q. Based on this evaluation, our President and Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures are effective to ensure that information we are required to disclose in reports that we file or submit under the Securities Exchange Act of 1934 is accumulated and communicated to our management, including our President and Chief Executive Officer and our Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure and that such information is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms.

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting that occurred during our most recent fiscal quarter that has materially affected or is reasonably likely to materially affect our internal control over financial reporting.

30

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

We are involved in various legal proceedings and receive claims from time to time, arising in the normal course of our business activities, including claims for alleged infringement or violation of intellectual property rights. We are not a party to any litigation that is expected to have a significant effect on our operations or business.

Item 1A. Risk Factors

A description of the risks and uncertainties associated with our business is set forth below. You should carefully consider such risks and uncertainties, together with the other information contained in this Quarterly Report on Form 10-Q and in our other public filings. If any of such risks and uncertainties actually occurs, our business, financial condition or operating results could differ materially from the plans, projections and other forward-looking statements included in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Part I, Item 2 of this Quarterly Report on Form 10-Q and elsewhere in this Quarterly Report on Form 10-Q and in our other public filings and public disclosures. In addition, if any of the following risks and uncertainties, or if any other risks and uncertainties, actually occurs, our business, financial condition or operating results could be harmed substantially, which could cause the market price of our stock to decline, perhaps significantly.

The Merger, the pendency of the Merger or our failure to complete the Merger could have a material adverse effect on our business, results of operations, financial condition and stock price.

Completion of the Merger is subject to the satisfaction of various conditions, including approval of the Merger by our shareholders, the absence of certain legal impediments, the absence of a material adverse effect on our business, and the approval of antitrust authorities in China and other foreign jurisdictions. There is no assurance that all of the various conditions will be satisfied, or that the Merger will be completed on the proposed terms, within the expected timeframe, or at all. Furthermore, there are additional inherent risks in the Merger, including the risks detailed below.

Risks related to the pendency of the Merger

During the period prior to the closing of the Merger, our business is exposed to certain inherent risks due to the effect of the announcement or pendency of the Merger on our business relationships, operations, results and business generally, including:

• potential uncertainty in the marketplace, which could lead current and prospective customers to purchase from other vendors or delay purchasing from us;

• the possibility of disruption to our business and operations, including diversion of management time and resources, increased transaction costs, and the potentially negative impact on our relationships with our suppliers;

• the inability to attract and retain key personnel, and the possibility that our current employees could be distracted, and their productivity decline as a result, due to uncertainty regarding the Merger;

• the inability to pursue alternative business opportunities or make changes to our business pending the completion of the Merger, and other restrictions on our ability to conduct our business;

• the fact that under the terms of the Merger Agreement, we are unable to solicit other acquisition proposals during the pendency of the Merger;

• the amount of the costs, fees, expenses and charges related to the Merger Agreement or the Merger; and

• other developments beyond our control, including, but not limited to, changes in domestic or global economic conditions that may affect the timing or success of the Merger.

Risks that the Merger may be delayed or may not be completed

The Merger may be delayed, and may ultimately not be completed, due to a number of factors, including:

• the failure to obtain the approval of the Merger Agreement by our shareholders;

• the failure to obtain regulatory approvals from various foreign governmental entities (or the imposition of any conditions, limitations or restrictions on such approvals);

• potential future shareholder litigation and other legal and regulatory proceedings, which could delay or prevent the Merger; and

• the failure to satisfy the other conditions to the completion of the Merger, including the possibility that a material adverse effect on our business would permit Thermo Fisher not to close the Merger.

31

Risks to our business if the Merger does not close

If the Merger does not close, our business and shareholders would be exposed to additional risks, including:

• to the extent that the current market price of our stock reflects an assumption that the Merger will be completed, the price of our common stock could decrease if the Merger is not completed;

• investor confidence could decline, shareholder litigation could be brought against us, relationships with existing and prospective customers, suppliers and other business partners may be adversely impacted, we may be unable to retain key personnel, and profitability may be adversely impacted due to costs incurred in connection with the pending Merger; and

• the requirement that we pay a termination fee of $175 million to Thermo Fisher if we terminate the agreement governing the Merger under certain circumstances.

Risks related to the successful completion of the Merger

Even if successfully completed, there are certain risks to our shareholders from the Merger, including:

• the amount of cash to be paid under the agreement governing the Merger is fixed and will not be adjusted for changes in our business, assets, liabilities, prospects, outlook, financial condition or results of operations or in the event of any change in the market price of, analyst estimates of, or projections relating to, our common stock; and

• the fact that, if the Merger is completed, shareholders will forego the opportunity to realize the potential long-term value of the successful execution of our current strategy as an independent company.

We operate in highly competitive industries, and we cannot be certain that we will be able to compete successfully in such industries.

The industries in which we operate are intensely competitive. Established companies, both domestic and foreign, compete with us in each of our product lines. Some of our competitors have greater financial, engineering, manufacturing and marketing resources than we do and may price their products very aggressively. In addition, these competitors may be willing to operate at a less profitable level than at which we would expect to operate. Our significant competitors include, among others: JEOL Ltd., Carl Zeiss SMT A.G., Hitachi High Technologies Corporation and Tescan, a.s. In addition, some of our competitors have formed collaborative relationships and otherwise may cooperate with each other.

To compete successfully, we must succeed in our R&D efforts, develop new products and production processes, and improve our existing products and processes ahead of competitors. Our R&D efforts are critical to our success and are aimed at solving complex problems, and we do not expect all of our projects to be successful. We may be unable to develop and market new products successfully, and the products we invest in and develop may not be well received by customers. Our R&D investments may not generate significant operating income or contribute to our future operating results for several years and such contributions may not meet our expectations or even cover the costs of such investments. Additionally, the products and technologies offered by others may affect demand for or pricing of our products. These types of events could negatively affect our competitive position and may reduce revenue, increase costs, lower gross margin percentages, or require us to impair our assets.

The identity and composition of our competitors may change as we increase our focus on application-specific workflows and new market opportunities, such as the oil and gas services sector and electrical fault isolation in the semiconductor sector. As we expand into new markets, we will face competition not only from our existing competitors, but also from other established competitors with stronger technological, marketing and sales positions in those markets.

Our customers must make a substantial investment to install and integrate capital equipment into their laboratories and process applications. For example, once a manufacturer has selected a particular vendor’s capital equipment, the manufacturer generally relies on that equipment for a specific production line or process control application and frequently will attempt to consolidate its other capital equipment requirements with the same vendor. Accordingly, if a particular customer selects a competitor’s capital equipment, we expect to experience difficulty selling to that customer for a significant period of time.

Our ability to compete successfully depends on a number of factors both within and outside of our control, including:

• price;

• product quality;

• breadth of product line;

• system performance;

• ease of use;

• type and breadth of product applications;

32

• cost of ownership;

• global technical service and support;

• success in developing or otherwise introducing new products; and

• foreign currency fluctuations.

We cannot be certain that we will be able to compete successfully based on these or other factors, which could negatively impact our revenues, gross margins and net income in the future.

Because most of our product shipments occur in the last month of a quarter, we are at risk of one or more transactions not being delivered according to forecast.

We have historically shipped approximately 70% of our products in the last month of each quarter. In addition, we rely on a significant amount of book and ship business (revenue from tools booked and sold in the same quarter) in any given quarter. Because any one sale may be significant to meeting our quarterly sales projection (as our average selling price for a tool is over $1 million), any slippage of shipments into a subsequent quarter may result in not meeting our quarterly sales projection, which may adversely impact our results of operations for the quarter.

Because we have significant operations outside of the U.S., we are subject to political, economic and other international conditions that could result in increased operating expenses, regulation of our products and difficulty in maintaining operating and financial controls, and which could otherwise adversely affect our industry, business and results of operations.

Because a significant portion of our operations occur outside of the U.S., our revenues and expenses are impacted by foreign economic and regulatory conditions. Approximately 68% of our sales came from outside the U.S. in both the twenty-six weeks ended July 3, 2016 and June 28, 2015. We have manufacturing facilities in Brno, Czech Republic, Eindhoven, The Netherlands and Munich, Germany and sales offices in many other countries. Over 75% of our products are manufactured in Europe.

Moreover, we operate in over 50 countries, including in 25 where we have a direct presence, and we are seeking to establish a direct presence in additional countries. Some of our global operations are geographically isolated, are distant from corporate headquarters and/or have little infrastructure support. Therefore, maintaining and enforcing operating and financial controls can be difficult. Failure to maintain or enforce controls could have a material adverse effect on our control over service inventories, quality of service, customer relationships and financial reporting.

Our exposure to the business risks presented by foreign economies will increase to the extent we continue to expand our global operations. International operations will continue to subject us to a number of risks, including:

• longer sales cycles;

• protectionist laws and business practices that favor local companies;

• price and currency exchange rates and controls;

• taxes and tariffs;

• difficulties in collecting accounts receivable;

• travel and transportation difficulties resulting from actual or perceived health risks;

• security concerns, such as armed conflict and civil or military unrest, political and economic instability and terrorist activity;

• risk of failure of internal controls and failure to detect unauthorized transactions; and

• changing and differing laws and regulations worldwide affecting our operations in areas including, but not limited to, intellectual property ownership and infringement, anti-corruption, import and export requirements, taxes, data privacy, competition, employment and environmental health and safety.

In addition, the future economic climate may be less favorable than that of the past. Any slowdown in global economic conditions has led, and could lead, to reduced consumer and business spending in the future, including by our customers and the purchasers of their products and services. If such spending slows down or decreases, our industry, business and results of operations may be adversely impacted.

The industries in which we sell our products are cyclical, which may cause our results of operations to fluctuate and changes in product demands from our customers may increase volatility and adversely impact our ability to forecast revenues.

Our business depends in large part on the capital expenditures of customers within our Industry Group and Science Group. See “Net Sales by Segment” included in Part I, Item 2 of this Quarterly Report on Form 10-Q for additional information.

33

The largest part of our Industry Group is revenue derived from the semiconductor industry. This industry is cyclical and has experienced significant economic downturns at various times in the last decade. Such downturns have been characterized by diminished product demand, accelerated erosion of average product selling prices and production overcapacity. A downturn in this industry, or the businesses of one or more of our customers, could have a material adverse effect on our business, prospects, financial condition and results of operations. During downturns, our sales and gross profit margins generally decline. In addition, the continued adoption of our near-line product solutions, which involves the sale of higher priced tools and longer lead times, has increased the volatility of our sales to this industry and our ability to accurately forecast revenues.

A significant portion of our Science Group revenue is dependent on government investments in research and development of new technology. To the extent that governments, especially in Europe or the U.S., reduce their spending in response to budget deficits, debt limitations or other factors, demand for our products could be affected. The funding cycles for our customers tend to extend over multiple quarters and several countries have reaffirmed their commitment to scientific research, but the longer-term impact of potential government fiscal austerity measures on our growth rate cannot be determined at this time.

As a capital equipment provider, our revenues depend in large part on the spending patterns of our customers, who could delay expenditures or cancel orders in reaction to variations in their businesses or general economic conditions. Because a high proportion of our costs are fixed, we have a limited ability to reduce expenses quickly in response to revenue shortfalls. In a prolonged economic downturn, we may not be able to reduce our significant fixed costs, such as manufacturing overhead, capital equipment or research and development costs, which may cause our gross margins to erode and our earnings to decline.

Our acquisition and investment strategy subjects us to risks associated with evaluating and pursuing these opportunities and integrating these businesses.

In addition to our efforts to develop new technologies from internal sources, we may also seek to acquire new technologies or operations from external sources. For example, on December 10, 2015 we acquired DCG Systems, Inc., a leading supplier of electrical fault characterization, localization and editing equipment, serving process development, yield ramp and failure analysis applications for a wide range of semiconductor and electronics manufacturers.

Acquisitions can involve numerous risks, including management issues and costs in connection with the integration of the operations and personnel, technologies and products of the acquired companies, legal and intellectual property issues, failure to properly integrate acquisitions, the possible write-downs of impaired assets and the potential loss of key employees of the acquired companies. The inability to effectively manage any of these risks could seriously harm our business. Additionally, difficulties in integrating our acquisitions into our internal control structure could result in a failure of our internal controls over financial reporting, which, in turn, could create a material weakness.

To the extent we make investments in entities that we control, or have significant influence in, our financial results will reflect our proportionate share of the financial results of the entity.

If our customers cancel or reschedule orders or if an anticipated order for even one of our systems is not received in time to permit shipping during a certain fiscal period, our operating results for that fiscal period may fluctuate and our business and financial results for such period could be materially and adversely affected. Cancellation risks rise in periods of economic uncertainty. Also, because we do not have long-term contracts with our customers, our customers may stop purchasing our products at any time, which makes it difficult to forecast our results of operations and to plan expenditures accordingly.

Our customers are able to cancel or reschedule orders, generally with limited or no penalties, depending on the product’s stage of completion. The amount of purchase orders at any particular date, therefore, is not necessarily indicative of sales to be made in any given period. In addition, we derive a substantial portion of our net sales in any fiscal period from the sale of a relatively small number of high-priced systems, with a large portion in the last month of the quarter. As a result, the timing of revenue recognition for a single transaction could have a material effect on our revenue and results of operations for a particular fiscal period.

Our build cycle, or the time it takes us to build a product to customer specifications, typically ranges from one to six months. During this period, the customer may cancel the order, although we may be entitled to receive a cancellation fee depending on the stage of completion. During the twenty-six weeks ended July 3, 2016 and June 28, 2015, we experienced cancellations of $8.9 million and $5.2 million, respectively.

Further, in some cases, our customers have to make changes to their facilities to accommodate the site requirements for our systems and may reschedule their orders because of the time required to complete these facility changes and for other reasons. This is particularly true of our high-performance TEMs, which often have specialized site requirements.

Our orders can have lead times of six to twelve months resulting in more orders scheduled for delivery of goods or services beyond 12 months. Individual orders can include many elements due to our customers ordering higher priced tools, placing multiple tool orders, and purchasing multi-year service contracts. Each of these factors may increase the volatility of our future revenue.

34

We do not have long-term contracts with our customers. Accordingly:

• customers can stop purchasing our products at any time without penalty;

• customers may cancel orders that they previously placed;

• customers may purchase products from our competitors;

• we are exposed to competitive pricing pressure on each order; and

• customers are not required to make minimum purchases.

Due to these and other factors, our net revenues and results of operations have fluctuated in the past and are likely to fluctuate significantly in the future on a quarterly and annual basis. It is possible that in some future quarter or quarters our results of operations will be below the expectations of public market analysts or investors. If we do not succeed in obtaining new sales orders from new and existing customers, our results of operations will be negatively impacted.

Due to our extensive international operations and sales, we are exposed to foreign currency exchange rate risks that could adversely affect our revenues, gross margins, results of operations and cash flows.

A significant portion of our sales and expenses are denominated in currencies other than the U.S. dollar, principally the euro and Czech koruna. During the twenty-six weeks ended July 3, 2016 and June 28, 2015, approximately 26% and 25% of our revenue was denominated in euros, respectively, while approximately half of our expenses were denominated in euros, Czech koruna, or other foreign currencies. Particularly as a result of this imbalance, changes in the exchange rate between the U.S. dollar and foreign currencies, principally the euro and Czech koruna, can impact our revenues, gross margins, results of operations and cash flows. We undertake hedging transactions primarily to limit our exposure to changes in the dollar/euro and dollar/Czech koruna exchange rates for up to one year. The hedges are designed to protect us as the dollar weakens but also provide us with some flexibility if the dollar strengthens. In addition, fluctuations in currency rates may negatively impact the demand for our products by making our products more expensive for our customers.

Achieving hedge designation is based on evaluating the effectiveness of the derivative contracts’ ability to mitigate the foreign currency exposure of the linked transaction. We are required to monitor the effectiveness of all new and open derivative contracts designated as hedges on a quarterly basis. Failure to meet the hedge accounting requirements could result in the requirement to record unrealized gains and losses into net income in the current period. This failure could result in significant fluctuations in operating results. In addition, we will continue to recognize unrealized gains and losses related to the changes in fair value of derivative contracts not designated as hedges in the current period net income. Accordingly, the related impact to operating results may be recognized in a different period than the foreign currency impact of the hedged transaction.

We also enter into foreign forward exchange contracts that are designed to partially mitigate the impact of specific cash, receivables or payables positions denominated in foreign currencies. See Note 15 of the Condensed Notes to the Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information.

The volatility of dollar/euro and dollar/Czech koruna exchange rates can make it more difficult for us to deploy our hedging program and create effective hedges or to achieve the desired outcome.

Our gross margins are dependent on many factors, some of which are not directly controlled by the company.

These factors are:

• significant variation in our gross margin among products. Any substantial change in product mix could change our gross margin;

• volatility of sales to our Industry Group customers contribute, on average, a higher proportion of our gross margin. Any significant downturn affecting these customers would have a negative impact on our gross margin;

• pricing and acceptance of higher-margin new products;

• realization of manufacturing efficiencies from our new facilities;

• realization of material cost savings through migration of the supply chain to lower cost suppliers and re-engineering of existing products;

• continued improvement in gross margins from our installed base; and

• movements in foreign currency exchange rates and impact of hedging.

Our inability to control any one of these factors could negatively impact our gross margins and operating results.

35

Our business is complex, and changes to the business may not achieve their desired benefits. In addition, many of our current and planned products are highly complex, creating manufacturing, planning and control challenges that may lead to higher costs and delays in product delivery, and our products may contain defects or errors that can only be detected after installation, which may harm our reputation and damage our business.

Our business is based on a myriad of technologies, encompassed in multiple different product lines, addressing various customers in a range of markets in different regions of the world. A business of our breadth and complexity requires significant management time, attention and resources. In addition, significant changes to our business, such as changes in manufacturing, operations, product lines, market focus or organizational structure or focus, can be distracting, time-consuming and expensive. These changes can have short-term adverse effects on our financial results. Moreover, we operate through various foreign subsidiaries that are subject to local corporate, labor and other laws. Specifically, the requirements that certain actions of our subsidiaries are subject to approval by local workers councils and supervisory boards could impair the company’s ability to take various actions and could result in unanticipated additional expense and delays. 

In addition, the complexity of product lines and diversity of our customer base creates manufacturing planning and control challenges that may lead to higher costs of materials and labor, increased service costs, manufacturing capacity issues, delays in production or shipments and excessive inventory. Our products incorporate leading-edge technology, including both hardware and software components, and software components may contain bugs that unexpectedly interfere with expected operations. There can be no assurance that our extensive product development, manufacturing and pre-shipment testing processes will be adequate to detect all defects, errors, failures and quality issues, which may interfere with customer satisfaction, reduce sales opportunities, affect gross margins or result in claims against us. Failure to effectively manage these manufacturing and product testing issues may result in the loss of, or delay in, market acceptance of our products, loss of sales, cancellation of orders, product returns, diversion of our resources, legal actions by our customers and other losses to us or our customers, which would harm our business and adversely affect our revenues and profitability. In addition, we may have to replace certain components and/or provide remediation in response to the discovery of defects in products after they are shipped. These factors could materially impact our financial position, results of operations or cash flow.

We rely on a limited number of suppliers to provide certain key parts and components. Failure of any of these suppliers to provide us with quality products in a timely manner could negatively affect our revenues and results of operations.

Failure of critical suppliers of parts, components and manufacturing equipment to deliver sufficient quantities to us in a timely and cost-effective manner could negatively affect our business, including our ability to convert backlog into revenue. Although we currently use numerous vendors to supply parts, components and subassemblies for the manufacture and support of our products, some key parts may only be obtained from a single supplier or a limited group of suppliers, some of which are also competitors. In particular, we rely on: VDL Enabling Technologies Group, NTS Group, Frencken Group Limited, Keller Technology, Schneeberger AG, Prodrive Technologies, Orsay Physics, Tektronix Inc., and AZD Praha s.r.o. for our supply of mechanical parts and subassemblies; Gatan, Inc., Edax Inc., Spellman High Voltage Electronics Corporation, Jenoptik, and Bruker Corp. for critical accessory products; and Neways Electronics, N.V. for some of our electronic subassemblies. A portion of the subcomponents that make up the components and sub-assemblies supplied to us are proprietary in nature and are provided to our suppliers only from single sources. We monitor those parts subject to single or a limited source supply to seek to minimize factory down time due to unavailability of such parts, which could impact our ability to meet manufacturing schedules. In addition, some of our suppliers rely on sole suppliers. As a result of this concentration of key suppliers, our results of operations may be materially and adversely affected if we do not timely and cost-effectively receive a sufficient quantity of quality parts to meet our production requirements or if we are required to find alternative suppliers for these supplies. We may not be able to expand our supplier group or to reduce our dependence on single suppliers. If our suppliers are not able to meet our supply requirements, constraints may affect our ability to deliver products to customers in a timely manner, which could have an adverse effect on our results of operations. In addition, restrictions regulating the use of certain hazardous substances in electrical and electronic equipment in various jurisdictions may impact parts and component availability or our electronics suppliers’ ability to source parts and components in a timely and cost-effective manner. Overall, our reliance on a limited group of suppliers for some parts, components and subassemblies creates exposure to potential future cost increases for our equipment.

Our service revenue depends on our ability to reliably diagnose maintenance and repair requirements and supply replacement parts and consumables to our customers. Failure to deliver high quality parts and consumables in a timely manner could cause our business to suffer.

Our installed base of approximately 10,700 tools includes diverse products of varying ages, configurations, use cases, condition, and customer requirements and is dispersed in approximately 50 countries around the world. Providing logistical support for delivery of spare parts and consumables to these tools, particularly the older tools, can be difficult. We have attempted to address the complexity of our maintenance and repair requirements, in part, through a remote diagnostics system that allows us to remotely access tools through a virtual private network. If we are unable to effectively manage and support the supply and delivery of spare parts and consumables to our customers we may damage our reputation and business.

36

Our business relies on various electronic data systems and their functioning is important to our business. Our business could be damaged if those systems fail or suffer a security breach or compromise.

We use a number of electronic data systems to help operate our business. If we are unable to maintain and safeguard our electronic data, our operating activities, financial reporting and intellectual property could be compromised, which may disrupt operations, harm our reputation and damage customer relationships. We also maintain personal information of our employees and a data breach that leads to the misuse or misappropriation of such information could cause the company to incur liability and damage our relationships with our employees, as well as our reputation. Moreover, if we suffer an unauthorized intrusion into our own systems or the virtual private network that provides remote tool diagnostics at customer sites, we, or our customers, may suffer a loss of proprietary information that could create liability for us and undermine our business. Further, if our systems are inaccessible for a period of time, it may compromise our ability to perform business functions in a timely manner. Costs to comply with and implement privacy-related and data protection measures could be significant.

Global privacy legislation, enforcement, and policy activity are rapidly expanding, changing and creating a complex compliance environment. Our failure to comply with federal, state, or international privacy-related or data protection laws and regulations could result in proceedings against us by governmental entities or others.

We depend on certain business processes for order entry and failure to adhere to those processes could impair our ability to properly book and fulfill orders.

We use business processes, including automated systems, to enter and track customer orders. Failure to adhere to these processes could result in errors in bookings, discounts on tool sales and failure to meet our global export compliance obligations. Further, inaccurate bookings information could lead to delays in shipping and having to rework orders. Such failures or inaccuracies could, in turn, cause us to suffer reduced margins, delayed revenue and governmental fines and penalties.

Our sales contracts often require delivery of multiple elements with complex terms and conditions that may cause our quarterly results to fluctuate.

Our system sales contracts include multiple elements such as delivery of more than one system, installation obligations (sometimes for multiple tools), accessories and/or service contracts, as well as provisions for customer acceptance. Typically, we recognize revenue as the various elements are delivered to the customer or the related services are provided. However, certain of these contracts have complex terms and conditions or technical specifications that require us to deliver most, or sometimes all, elements under the contract before revenue can be recognized. This could result in a significant delay between production and delivery of products and when revenue is recognized, which may cause volatility in, or adversely impact, our quarterly results of operations and cash flows.

The loss of one or more of our key customers would result in the loss of significant net revenues.

In the twenty-six weeks ended July 3, 2016 and June 28, 2015, our top 10 customers accounted for approximately 29% and 33% of our total annual net revenue, respectively. No customers accounted for 10% or more of total annual net revenue during the twenty-six weeks ended July 3, 2016 and June 28, 2015. Our business will be seriously harmed if we do not generate as much revenue as we expect from these key customers, if we experience a loss of any of our key customers or if we suffer a substantial reduction in orders from these customers. Our ability to continue to generate revenues from our key customers will depend on our ability to introduce new products that are desirable to these customers.

Certain of our significant customers have adopted policies relating to sustainability, supply chain management, disaster recovery and other initiatives that may result in significant additional costs depending on the actions we must take in order to comply. Our failure to comply with such policies and initiatives could result in loss of customer contracts or relationships, resulting in significant harm to our business.

We may not be able to enforce our intellectual property rights, especially in foreign countries, which could have a material adverse effect on our business.

Our success depends in large part on the protection of our proprietary rights. We generally rely on patents, copyrights, trademarks and trade secret laws to establish and maintain proprietary rights in our technology, products and services. We incur significant costs to obtain and maintain patents and other intellectual property rights and to defend our intellectual property. We also rely on the laws of the U.S. and other countries where we develop, manufacture or sell products and services to protect our proprietary rights. We may not be successful in protecting these proprietary rights, these rights may not provide the competitive advantages that we expect or other parties may challenge, invalidate or circumvent these rights. More specifically, we depend on trade secrets used in the development and manufacture of our products and delivery of our services. We endeavor to protect these trade secrets, but the measures taken to protect them may be inadequate or ineffective. These risks may increase as we focus on application-specific workflows and certain market opportunities, such as those in the oil and gas services sector, where key aspects of our technology may be made publicly available to competitors and new market entrants.

37

Further, our efforts to protect our intellectual property may be less effective in some countries where intellectual property rights are not as well protected as they are in the U.S. Approximately 68% of our sales came from outside the U.S. during both the twenty-six weeks ended July 3, 2016 and June 28, 2015, and a failure to adequately protect our intellectual property rights in these countries could have a material adverse effect on our business.

Infringement of our proprietary rights could result in weakened capacity to compete for sales and increased litigation costs, both of which could have a material adverse effect on our business, product gross margins, prospects, financial condition and results of operations.

If third parties assert that we violate their intellectual property rights, our business and results of operations may be materially adversely affected.

Some of our competitors hold patents or other intellectual property rights covering a variety of technologies that may be included in some of our products and services. In addition, some of our customers may use our products for applications that are similar to those covered by these patents or other intellectual property rights. From time to time, we, and our respective customers, have received correspondence from our competitors claiming that some of our products, as sold by us or used by our customers, may infringe one or more of these patents or other intellectual property rights. Any claim of infringement from a third party, even ones without merit, could cause us to incur substantial costs in defending ourselves against the claim and distract our management from running the business.

In addition, our competitors or other entities, including non-practicing entities, may assert infringement claims against us or our customers in the future with respect to current or future products or uses, and these assertions, even those without merit, may result in costly litigation or require us to obtain a license to use intellectual property rights of others. Additionally, if claims of infringement are asserted against our customers, those customers may seek indemnification from us for damages or expenses they incur.

If we become subject to additional infringement claims, we will evaluate our position and consider the available alternatives, which may include seeking licenses to use the technology in question, developing non-infringing technology or defending our position. These licenses, however, may not be available on satisfactory terms or at all. If we are not able to negotiate the necessary licenses on commercially reasonable terms, develop non-infringing technology or successfully defend our position, these potential infringement claims could have a material adverse effect on our business, prospects, financial condition and results of operations.

Our exposure to risks and costs associated with the protection and use of intellectual property may be increased as a result of acquisitions due to our lower level of visibility into the development process with respect to such technology, the care taken to safeguard against infringement risk or differences in the risk profile of the acquired intellectual property.

If we are unable to pay quarterly dividends or repurchase our stock at intended levels, our reputation and stock price may be harmed.

In May 2015, our Board of Directors reauthorized our share repurchase program. Under the reauthorization, which expires in May 2017, we may repurchase up to 2.0 million shares of our common stock. As of July 3, 2016, approximately 0.9 million shares of our common stock remained available for repurchase pursuant to our share repurchase program. In June 2012, our Board of Directors approved the initiation of quarterly cash dividends to holders of our common stock and dividends have been paid under this program each quarter since its inception in June 2012. The declaration and payment of dividends to shareholders in the future is subject to the discretion of our Board of Directors and capital availability. The dividend and stock repurchase program may require the use of a significant portion of our cash earnings. As a result, we may not retain a sufficient amount of cash to fund our operations or finance future growth opportunities, new product development initiatives and unanticipated capital expenditures. Further, our Board of Directors may, at its discretion, decrease the intended level of dividends or entirely discontinue the payment of dividends at any time, as well as limit, suspend or discontinue our stock repurchase program at any time. Our ability to pay dividends and repurchase stock will depend on our ability to generate sufficient cash flows from operations in the future. This ability may be subject to certain economic, financial, competitive and other factors that are beyond our control. Any failure to pay dividends or repurchase stock after we have announced our intention to do so may negatively impact our reputation and investor confidence in us and may negatively impact our stock price.

Restructuring activities may be disruptive to our business and financial performance. Any delay or failure by us to execute planned cost reductions could also be disruptive and could result in total costs and expenses that are greater than expected.

From time to time, we have engaged in various restructuring and infrastructure improvement programs in order to increase operational efficiency, consolidate sites, reduce costs and balance the effects of currency fluctuations on our financial results. These actions have included reductions of work-force, site consolidations, and migrating portions of our supply chain to dollar-linked contracts.

Restructuring has the potential to adversely affect our business, financial condition and results of operations due to potential disruption of manufacturing operations, our supply chain and other aspects of our business. Employee morale and productivity could also suffer and result in unintended employee attrition. Loss of sales, service and engineering talent, in particular, could

38

damage our business. Restructuring requires substantial management time and attention and has the potential to divert management from other important work. Moreover, we could encounter delays in executing our plans, which could cause further disruption and additional unanticipated expense. Some of our employees work in certain regions, such as Europe and Asia, where workforce reductions are highly regulated, and this could slow the implementation of planned workforce reductions. Restructuring plans may also fail to achieve the stated aims for reasons similar to those described in this paragraph.

During the course of executing a restructuring, we could incur material non-cash charges such as write-downs of inventories or other tangible assets. We test our goodwill and other intangible assets for impairment annually or when an event occurs indicating a potential for impairment. If we record an impairment charge as a result of our analysis, it could have a material impact on our results of operations.

Many of our projects are funded under various government contracts and if we are found to have violated the terms of the government contracts or applicable statutes and regulations, we are subject to the risk of suspension or debarment from government contracting activities, which could have a material adverse effect on our business and results of operations.

Many of our projects are funded under various government contracts worldwide. Government contracts are subject to specific procurement regulations, contract provisions and requirements relating to the formation, administration, performance and accounting of these contracts. Many of these contracts include express or implied certifications of compliance with applicable laws and contract provisions. As a result of our government contracting, claims for civil or criminal fraud may be brought by the government for violations of these regulations, requirements or statutes. Further, if we fail to comply with any of these regulations, requirements or statutes, our existing government contracts could be terminated, we could be suspended or debarred from government contracting or subcontracting, including federally funded projects at the state level. If one or more of our government contracts are terminated for any reason, or if we are suspended from government work, we could suffer the loss of future contracts, which could have a material adverse effect on our business and results of operations.

Changes and fluctuations in government spending priorities and procurement practices could adversely affect our revenue.

Because a significant part of our overall business is generated either directly or indirectly as a result of international, national and local government regulatory and infrastructure priorities, shifts in these priorities due to changes in policy imperatives or economic conditions or government administration, which are often unpredictable, may affect our revenues.

Political instability in key regions around the world, the U.S. government’s commitment to military-related expenditures and current uncertainty around global sovereign debt put at risk federal discretionary spending, including spending on nanotechnology research programs and projects that are of particular importance to our business. Also, changes in U.S. Congressional appropriations practices could result in decreased funding for some of our customers. At the state and local levels, the need to compensate for reductions in federal matching funds, as well as financing of federal unfunded mandates, creates strong pressures to cut back on research expenditures as well. A potential reduction of federal funding may adversely affect our business.

In addition, procurement practices and procedures vary widely in the various jurisdictions where we conduct business and changes in these practices and procedures could cause delay in obtaining orders and revenue. The anti-corruption measures undertaken by the Chinese government in its procurement practices have caused some delay in orders and revenue from Chinese government-controlled or related entities and these orders and revenue may continue to be delayed to the extent that these anti-corruption measures continue to be undertaken by the Chinese government.   

We have long sales cycles for our systems, which may cause our results of operations to fluctuate.

Our sales cycle can be 18 months or longer and is unpredictable. Variations in the length of our sales cycle could cause our net sales and, therefore, our business, financial condition, results of operations, operating margins and cash flows, to fluctuate widely from period to period. These variations could be based on factors partially or completely outside of our control.

The length of time it takes us to complete a sale depends on many factors, including:

• the efforts of our sales force and our independent sales representatives;

• changes in the composition of our sales force, including the departure of senior sales personnel;

• the history of previous sales to a customer;

• the complexity of the customer’s manufacturing processes;

• the introduction, or announced introduction, of new products by our competitors;

• the economic environment;

• the internal technical capabilities and sophistication of the customer; and

• the capital expenditure budget cycle of the customer.

39

Our sales cycle also extends in situations where the sale involves developing new applications for a system or technology. As a result of these and a number of other factors that could influence sales cycles with particular customers, the period between initial contact with a potential customer and the time when we recognize revenue from that customer, if we ever do, may vary widely.

The loss of key management or our inability to attract and retain managerial, engineering and other technical personnel could have a material adverse effect on our business, financial condition and results of operations.

Attracting qualified personnel is difficult, and our recruiting efforts may not be successful. Specifically, our product generation efforts depend on hiring and retaining qualified engineers, the market for which is very competitive. In addition, experienced management and technical, sales, marketing and service personnel in the technology industry are in high demand, and competition for such talent is intense. The loss of key personnel, or our inability to attract key personnel, could have an adverse effect on our business, financial condition or results of operations.

Our customers experience rapid technological changes, with which we must keep pace. We may be unable to properly ascertain new market needs, or introduce new products responsive to those needs, on a timely and cost-effective basis.

Our customers experience rapid technological change that requires new product introductions and enhancements. Our ability to remain competitive depends in large part on our ability to understand these changes and develop, in a timely and cost-effective manner, new and enhanced systems at competitive prices that respond to, and accurately predict, new market requirements. We may fail to ascertain and respond to the needs of our customers or fail to develop and introduce new and enhanced products that meet their needs, which could adversely affect our financial position. In addition, new product introductions or enhancements by competitors could cause a decline in our sales or a loss of market acceptance of our existing products. Increased competitive pressure also could lead to intensified price competition, resulting in lower margins, which could materially adversely affect our business, prospects, financial condition and results of operations.

Our success in developing, introducing and selling new and enhanced systems depends on a variety of factors, including:

• selection and development of product offerings;

• timely and efficient completion of product design and development;

• timely and efficient implementation of manufacturing processes;

• effective sales, service and marketing functions; and

• product performance.

Because new product development commitments must be made well in advance of sales, new product decisions must anticipate both the future demand for products under development and the equipment required to produce such products. We cannot be certain that we will be successful in selecting, developing, manufacturing and marketing new products or in enhancing existing products. On occasion, certain product and application developments have taken longer than expected. These delays can have an adverse effect on product shipments and results of operations.

The process of developing new high technology capital equipment products and services is complex and uncertain, and failure to accurately anticipate customers’ changing needs and emerging technological trends, to complete engineering and development projects in a timely manner and to develop or obtain appropriate intellectual property could significantly harm our results of operations. We must make long-term investments and commit significant resources before knowing whether our predictions will result in products that the market will accept.

To the extent that a market does not develop for a new product, we may decide to discontinue or modify the product. These actions could involve significant costs and/or require us to take charges in future periods. If these products are accepted by the marketplace, sales of our new products may cannibalize sales of our existing products. Further, after a product is developed, we must be able to manufacture sufficient volume quickly and at low cost. To accomplish this objective, we must accurately forecast production volumes, mix of products and configurations that meet customer requirements. If we are not successful in making accurate forecasts, our business and results of operations could be significantly harmed.

We may have exposure to income tax rate fluctuations as well as to additional tax liabilities, which would impact our financial position.

We are subject to income taxes in the U.S. and various foreign jurisdictions. Our effective tax rate is subject to significant fluctuation from one period to the next as the income tax rates for each year are a function of the following factors, among others:

• the effects of a mix of profits or losses earned by us and our subsidiaries in numerous foreign tax jurisdictions with a broad range of income tax rates;

• our ability to utilize recorded deferred tax assets;

• changes in uncertain tax positions, interest or penalties resulting from tax audits; and

40

• changes in tax rates and laws or the interpretation of such laws.

Changes in the mix of these items and other items may cause our effective tax rate to fluctuate between periods, which could have a material adverse effect on our financial results.

Recently, the Organisation for Economic Co-operation and Development (“OECD”) released a series of reports in support of the Base Erosion and Profit Shifting (“BEPS”) Project, which provides governments with solutions for international tax reforms. Changes to tax laws, regulations, and reporting requirements as a result of the BEPS Project could adversely impact our effective tax rate and cash flows, and have a negative effect on our financial results.

We are also subject to non-income taxes, such as payroll, sales, use, value-added, net worth, property and goods and services taxes, in both the U.S. and various foreign jurisdictions.

We are regularly under audit by tax authorities with respect to both income and non-income taxes and may have exposure to additional tax liabilities as a result of these audits.

Significant judgment is required in determining our provision for income taxes and other tax liabilities. Although we believe that our tax estimates are reasonable, we cannot assure you that the final determination of tax audits or tax disputes will not be different from what is reflected in our historical income tax provisions and accruals.

Some of our systems use hazardous gases and high voltage power supplies as well as emit x-rays, which, if not properly contained, could result in property damage, bodily injury and death.

A product safety failure, such as a hazardous gas release, high voltage power supply problem, x-ray leak or extreme pressure release, could result in substantial liability and could also significantly damage customer relationships and our reputation and disrupt future sales. Moreover, remediation could require redesign of the tools involved, creating additional expense, increasing tool costs and damaging sales. In addition, a product safety failure could involve significant litigation that would divert management time and resources and cause unanticipated legal expense. Further, if such a failure involved violation of health and safety laws, we may suffer substantial fines and penalties in addition to the other damages suffered. Finally, failure to properly manage the regulatory requirements for shipment of dangerous products could cause delays in clearing customs and thereby cause delay or loss of revenue in any particular quarter.

Natural disasters, catastrophic events, terrorist acts and acts of war may seriously harm our business and revenues, costs and expenses and financial condition.

Our worldwide operations could be subject to earthquakes, volcanic eruptions, telecommunications failures, power interruptions, water shortages, closure of transport routes, tsunamis, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics or pandemics, terrorist acts, acts of war and other natural or manmade disasters or business interruptions. For many of these events we carry no insurance. The occurrence of any of these business disruptions could seriously harm our revenue and financial condition and increase our costs and expenses. The impact of such events could be disproportionately greater on us than on other companies as a result of our significant international presence. Our corporate headquarters, and a portion of our research and development activities, are located on the Pacific coast, and other critical business operations and some of our suppliers are located in Asia, near major earthquake faults. We rely on major logistics hubs, primarily in Europe, Asia and the U.S. to manufacture and distribute our products and to move products to customers in various regions. Our operations could be adversely affected if manufacturing, logistics or other operations in these locations are disrupted for any reason, including those described above. The ultimate impact of our consolidation in certain geographical areas on us, our significant suppliers and our general infrastructure is unknown, but our revenue, profitability and financial condition could suffer in the event of a catastrophic event.

Unforeseen health, safety and environmental costs could impact our future net earnings.

Some of our operations use substances that are regulated by various federal, state and international laws governing health, safety and the environment. We could be subject to liability if we do not handle these substances in compliance with safety standards for storage and transportation and applicable laws. We will record a liability for any costs related to health, safety or environmental remediation when we consider the costs to be probable and the amount of the costs can be reasonably estimated.

Changes in accounting pronouncements or taxation rules or practices may affect how we conduct our business.

Changes in accounting pronouncements or taxation rules or practices can have a significant effect on our reported results. New accounting pronouncements or taxation rules and varying interpretations of accounting pronouncements or taxation practices have occurred and may occur in the future. New rules, changes to existing rules, or the questioning of current practices may adversely affect our reported financial results or change the way we conduct our business.

41

Provisions of our charter documents and Oregon law could make it more difficult for a third party to acquire us, even if the offer may be considered beneficial by our shareholders.

Our articles of incorporation and bylaws contain provisions that could make it harder for a third party to acquire us without the consent of our Board of Directors. In addition, the Oregon Control Share Act and the Oregon Business Combination Act limit the ability of parties who acquire a significant amount of voting stock to exercise control over us. These provisions may have the effect of lengthening the time required for a person to acquire control of us through a proxy contest or the election of a majority of our Board of Directors, may deter efforts to obtain control of us and may make it more difficult for a third party to acquire us without negotiation. These provisions may apply even if the offer may be considered beneficial by our shareholders.

42

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

In May 2015, our Board of Directors reauthorized our share repurchase program. Under the reauthorization, which expires May 29, 2017, we may repurchase up to 2.0 million shares of our common stock. The amount and timing of specific repurchases are subject to market conditions, applicable legal requirements and other factors. The repurchases are funded from existing cash resources and may be suspended or discontinued at any time at our discretion without prior notice.

We did not repurchase any shares of our common stock during the thirteen week period ended July 3, 2016. As of July 3, 2016, 922,004 shares remained available for repurchase pursuant to our share repurchase program.

43

Item 6. Exhibits

The following exhibits are filed herewith or incorporated by reference hereto and this list is intended to constitute the exhibit index:

2.1	Agreement and Plan of Merger, dated as of May 26, 2016, among FEI Company, Thermo Fisher Scientific Inc., and Polpis Merger Sub Co. (1)
3.1	Third Amended and Restated Articles of Incorporation.(2)
3.2	Articles of Amendment to the Third Amended and Restated Articles of Incorporation.(3)
3.3	Amended and Restated Bylaws, as amended on September 15, 2014.(4)
10.1	1995 Stock Incentive Plan, as amended. (5)
31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of The Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of The Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of The Sarbanes-Oxley Act of 2002.
32.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of The Sarbanes-Oxley Act of 2002.
101.INS	XBRL Instance Document.
101.SCH	XBRL Taxonomy Extension Schema Document.
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.

(1) Incorporated by reference to our Current Report on Form 8-K filed with the Securities and Exchange Commission on June 2, 2016.

(2) Incorporated by reference to our Quarterly Report on Form 10-Q for the quarter ended September 28, 2003.

(3) Incorporated by reference to our Current Report on Form 8-K filed with the Securities and Exchange Commission on July 27, 2005.

(4) Incorporated by reference to our Current Report on Form 8-K filed with the Securities and Exchange Commission on September 16, 2014.

(5) Incorporated by reference to our Current Report on Form 8-K filed with the Securities and Exchange Commission on May 12, 2016.

The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of FEI Company under the Securities Act, or the Securities Exchange Act of 1934, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.

44

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		FEI COMPANY
Dated:	August 4, 2016	/s/ Don R. Kania
		Don R. Kania
		President and Chief Executive Officer
		(Principal Executive Officer)
Dated:	August 4, 2016	/s/ Anthony L. Trunzo
		Anthony L. Trunzo
		Executive Vice President and Chief Financial Officer
		(Principal Financial Officer)

45